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Summary: Invariant natural killer T (iNKT)/natural killer (NK)/
cytokine-induced killer (CIK) cells are important for immune
surveillance. (I) Novel combinations of antibody 6B11 (targeting
the Va24-Ja18-invariant T-cell receptor) with CD4/CD8/CD1d/
Va24 for iNKT subset detection and “T/NK cell-like”-iNKT
subsets were defined. Compared with healthy peripheral blood
mononuclear cells (MNC) (significantly) lower proportions of
iNKT cells (6B11+/6B11+CD3+/6B11+CD161+), NK cells
(CD3CD56+/CD3CD161+), and CIK cells (CD3+CD56+/
CD3+CD161+) were found in peripheral blood MNC from acute
myeloid (AML)/acute myeloid, lymphoid (ALL)/chronic lymphoid
leukemia (CLL) patients in acute disease stages. Subtyping of
iNKT cells revealed (significantly) higher proportions of CD3+
T cells and CD161+ NK cells in AML/ALL/CLL expressing 6B11
compared with healthy MNC. Prognostic evaluations showed
higher proportions of iNKT/NK/CIK cells in favorable AML
subgroups (younger age, primary, no extramedullary disease, ach-
ievement/maintenance of complete remission) or adult ALL and
CLL patients. (II) iNKT/NK/CIK cell frequencies increased after
(vs. before) mixed lymphocyte cultures of T-cell–enriched immune
reactive cells stimulated with MNC/whole blood with or without
pretreatment with “cocktails” (dendritic cells generating methods/
kits inducing blasts’ conversion to leukemia-derived dendritic cells
from AML patients). Individual “cocktails” leading to “highest”
iNKT cell frequencies could be defined. Antileukemic blast lytic
activity correlated significantly with frequencies of iNKT/NK/CIK
cells. In summary healthy MNC show significantly more iNKT/
NK/CIK cells compared with AML/ALL/CLLMNC, a shift in the
iNKT cell composition is seen in healthy versus leukemic samples
and iNKT/NK/CIK cell-proportions in AML/ALL/CLL MNC
samples correlate with prognosis. “Cocktail”-treated AML blasts
lead to higher iNKT/NK/CIK cell frequencies and samples with
antileukemic activity show significantly higher frequencies of
iNKT/NK/CIK cells. Proportions of iNKT/NK/CIK cells should
regularly be evaluated in AML/ALL/CLL diagnosis panels for
quantitative/prognostic estimation of individual patients’ anti-
leukemic potential and their role in dendritic cells/leukemia-derived
dendritic cells triggered immune surveillance.
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Acute myeloid (AML), lymphoid (ALL) or chroniclymphoid leukemia (CLL) are clonal diseases with
uncontrolled proliferation of myeloid or lymphoid blasts.
Prognostic rates of complete remission (CR) and survival
depend on grade of anemia, thrombocytopenia, white
blood cell expansion and karyotypes, resulting in different
therapeutic strategies. Therapy for AML, ALL, and CLL
patients with advanced stages consists of chemotherapy and
stem cell transplantation (SCT), but the rate of early fail-
ures and relapses is still unsatisfying. AML patients can be
categorized into 3 risk groups.1 ALL patients are primarily
children with survival rates of about 90% and higher inci-
dences for an assignment to standard risk-groups compared
with adult patients with higher tendencies for high risk
leukemia.2 CLL usually occurs in elderly patients and these
are classified in Binet-staging groups: Binet A (early),
B (intermediate), and C (advanced stage).3
Effective immune surveillance of patients with hema-
tologic malignancies such as leukemia is mediated by arms
of the innate and adaptive immune system. The innate
immune system includes macrophages, dendritic cells (DC),
and natural killer (NK) cells, which respond quickly to an
immunologic threat.4 NK cells have the ability to kill tumor
cells without activation, arise from CD34+ bone marrow
(BM) cells and are defined as CD3CD56+CD161+.5 The
adaptive immune system includes T and B cells, which
mediate tumor immunity by antigen-specific responses and
provide long-lasting protection by effector-memory
responses. T cells (CD3+) express T-cell receptors (TCR)
that recognize (peptide)-antigens on blasts, which have to
be presented by majorhistocompatibility complex (MHC)-I
or MHC-II molecules via antigen-presenting cells.4
A specialty of myeloid blasts is, that they can differentiate
to leukemia-derived dendritic cells (DCleu), presenting the
complete leukemic antigen repertoire, thereby specifically
and efficiently activating an antileukemic T-cell response.6–8
T cells occur in various differentiation and functional sub-
sets [eg, naive (Tnaive, CD45RO
), non-naive (Tnon-naive,






other cells at the interface of the innate and the adaptive
immune system are important mediators in antitumor,
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autoimmune, and antimicrobial responses and tumor sur-
veillance4: cytokine-induced killer (CIK) cells have pheno-
typic and functional features of T and NK cells as they are
CD3+CD56+CD161+, they are expandable in culture
like T cells; however, they do not recognize cells via TCR or
MHC molecules as T cells.5 NKT cells are a heterogenous
lymphoid population, that bridge innate and adaptive
immunity and, in general, share properties of T and NK
cells. Similar to NK cells, NKT cells have the ability to
react rapidly to antigenic stimulation by quickly secreting
large amounts of cytokines and chemokines within minutes
to hours.4 In addition, they activate DC, NK, and CD4+/
CD8+ T cells, thereby triggering innate and adaptive
immune responses.11 Similar to T cells, NKT cells respond
via the TCR, recognizing glycolipid antigens presented by
the MHC-like molecule CD1d. TCR from NKT cells react
with many self and foreign antigens, while the TCR from
T cells only reacts with one epitope.4 It was shown, that
the positive selection of NKT cells is strictly dependent
on CD1d during ontogeny in the thymus and therefore
CD1d restriction has become the defining characteristic of
NKT cells (NK markers are only used to define sub-
populations).12 The NKT cell population consists of many
phenotypically and functionally diverse subsets, which are
subdivided either by surface markers, TCR, tissue location,
antigen recognition or by effector functions. Concerning
their heterogenous TCR rearrangements, NKT cells are
divided into 2 main groups: type-I NKT cells are referred to
as invariant NKT cells (iNKT cells) as they express a semi-
invariant TCR, characterized in humans by Va24-Ja18 and
Vb11, while b-chains have a limited variety. In contrast,
NKT cells that do not express this semi-invariant TCR are
referred to as type-II NKT cells, which are less well studied
than iNKT cells.11 iNKT cells are known for enhancement
of tumor immunity, while type-II NKT cells are known for
suppression of it, resulting in opposed roles in tumor
immunity and crossregulate of each other.4
NKT cells originate from a precursor pool of CD4+
CD8+ double positive thymocytes, that have to undergo
diverse TCR gene rearrangements, are then positively
selected by CD1d+ double positive thymocytes in the
thymic cortex, undergo 4 differentiation and maturation
steps and then differentiate into mature NKT cells.
Expression of CD4 and CD8 allow a subdivision of NKT
cells in different subpopulations: a majority is CD4+ (90%
in mice), the remainder is CD4CD8 double negative
and a small population is CD8aa+ and CD8ab+, but CD8+
subsets only exist in humans (not in mice), predominantly in
healthy persons with latent Epstein-Barr virus infection.12
The evaluation of human iNKT cells is challenging, as
their frequency in peripheral blood (PB) is very low. Clas-
sically, iNKT cells have been identified using CD1d tet-
ramers loaded with a-galactosylceramide or monoclonal
antibodies (moAbs) against the Va24 and Vb11 chains,
what however, can lead to an overestimation of iNKT cells,
as noninvariant, non-CD1d restricted Va24+ T cells
can also pair with Vb11. Recently iNKT cells were
shown to be identified using the moAb 6B11, which rec-
ognizes the invariant CDR3 loop of their Va24Ja18 TCR-
rearrangement with high specificity and sensitivity.13
CD161 (NKR-P1A) is a C-type lectin receptor and is an
important marker for NK and iNKT cell identification as
all human NK cells, high proportions of iNKT cells,
and Teff/em and Tcm express it. Recently it was shown,
that CD161+ T cell subsets are highly functional during
infections: low frequencies correlate with higher incidence
of (viral) infections.14–18
Considering that the antileukemic function of T cells
can be stimulated by DCleu,
9,10 our supposition is that the
iNKT/NK and CIK cell activity might also be enhanced
under DC/DCleu stimulation. DCleu can be generated
in vitro by converting myeloid leukemia cells in mono-
nuclear cells (MNC) or whole blood (WB) using DC-
generating methods/kits (“cocktails,” containing immune
response modifiers in combination with cytokines) and
represent as well leukemic (eg, CD13, CD33, CD117) and
DC antigens (eg, CD80, CD83, CD86).19,20
Physiological conditions in the stem cell niche of the
BM as well as in the PB are hypoxic with Oxygen (O2)
concentrations between 0.1% and 0.6 % in the BM, 12% in
arterial blood and 4%–15% in PB.21,22 Previous studies
suggest an influence of the partial pressure of oxygen (pO2)
on several pathophysiological mechanisms.23,24 However,
hematopoiesis takes place under physiologically low pO2/
O2-concentration and hematopoietic cells are continually
exposed to dynamic pO2-values.
25 Moreover, a recent
in vitro study showed that hypoxia might have an
enhancing effect on NK cells.26
The aim of this study was (1) to test the suitability of
different markers and combinations (Table 1) to charac-
terize and quantify iNKT, NK, and CIK cells/subsets; (2)
to quantify iNKT, NK, and CIK subsets in MNC from
patients with AML, ALL, and CLL compared with healthy
controls; (3) to correlate findings with disease entities and
prognostic subgroups; (4) to quantify iNKT, NK, and CIK
subsets under stimulation with DC/DCleu, that are gen-
erated from WB/MNC with various “cocktails”.
MATERIALS AND METHODS
Sample Collection
After obtaining informed consent, heparinized
peripheral WB samples were taken from patients in acute
phases of AML, ALL, CLL, and from healthy controls.
MNC were prepared from WB samples by density gradient
centrifugation using the Ficoll-Hypaque technique (Biocoll
separating solution; Biochrom, Berlin, Germany) with a
density gradient of 1.077 g/mL. MNC were washed and
suspended in phosphate-buffered saline (PBS; Biochrom).
CD3+ T cells were enriched using the MACS technology
(Milteney Biotech, Bergisch Gladbach, Germany). The
purity of CD3+ T cells was on average (Ø) 89% (range:
69%–98%). Cells were quantified using Neubauer counting
chambers, used directly or frozen and thawed according to
standardized protocols.
Patients’ Characteristics and Diagnostics
Patients and Samples Included for Surface Marker
Expression Analyses on Thawed Cells
Quantitative and qualitative characterizations of
several immune reactive cells were performed with thawed
MNC from patients with blast-rich phases of AML
(n=23), ALL (n=19), and CLL (n=21). Samples were
provided by the University-Hospitals of Tubingen, Dus-
seldorf, Munich, Oldenburg and Augsburg. Cells were
obtained by aspirates of PB or BM, which were anti-
coagulated with heparin after patients’ written informed
consent in accordance with the Helsinki protocol and the
local Ethic Committee (Pettenkoferstr. 8a, 80336 München,
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TABLE 1. Subtypes of T/iNKT/NK/CIK Cells, Blasts and DC as Evaluated by Flow Cytometry
Matsuda et al51
Matsuda et al51
Surface marker combinations as well as T/iNKT/NK/CIK cell and DC subtypes after flow cytometric staining with fluorochrome-labeled antibodies are
given.
*Total proportions of cell subsets in uncultured MNC/WB or in MLC (after culture with T cells and IL-2).
wCells expressing blast markers: patients’ individually selected blast-markers with the highest expression (Table 2: blast phenotype).
CIK indicates cytokine-induced killer; DC, dendritic cells; iNKT, invariant natural killer T; NK, natural killer; MLC, mixed lymphocyte cultures; MNC,
mononuclear cells; WB, whole blood.
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Ludwigs-Maximilians-University Hospital in Munich;
Vote-No 339-05). The mean age of AML patients was 50
(range: 23–81) years, of ALL patients 22 (range: 3–50) years
and of CLL patients 57 (range: 33–72) years. The female to
male ratio of AML patients was 1:1.9, of ALL patients was
1:1.7, and of CLL patients was 1:0.9 (Table 2A).
Diagnosis and classification of AML patients was
based on the “French American British” classification:
minimally differentiated AML (M0: n=1), AML without
maturation (M1: n=6), AML with granulocytic matura-
tion (M2: n=6), acute myelomonocytic leukemia (M4:
n=4), acute myelomonocytic leukemia together with BM
eosinophilia (M4eo: n=2), acute monocytic leukemia (M5:
n=3). Patients presented with primary AML (n=18) or
with secondary AML (n=5). Patients stages were: first
diagnosis (n=20), relapse before (n=1) or after SCT
(n=2). Patients were classified in cytogenetic risk groups
based on the National Comprehensive Cancer Network
(NCCN) guidelines as “favorable” (n=3), “intermediate”
(n=11), or “adverse risk” (n=4); for 5 patients no further
data were available.
The subtypes of the 19 ALL patients were immune
cytologically classified according to the European Group
of Immunophenotyping of Leukemias classification: pro
B-ALL (BI: n=1), c ALL (BII: n=5), pre B-ALL (BIII:
n=2), My+c ALL (BII+My: n=3), My+pre B-ALL
(BIII+My: n=1), pro T-ALL (TI: n=1), pre T-ALL
(TII: n=1), cortical T ALL (TIII: n=4), mature T ALL
(TIV:n=1). Patients presented with primary ALL (n=5)
or with secondary ALL (n=14). Stages of samples were:
diagnosis before SCT (n=17) or at relapse after SCT
(n=2). Risk stratification of adult ALL was based on the
Study Group for Adult Acute Lymphoblastic Leukemia
(GMALL) as “standard” (n=3), “high” (n=1) or
“highest risk” (n=3); for 12 patients no further data were
available.
All CLL patients were classified as pB-CLL (n=21)
at diagnosis (n=2) or with persisting disease (n=19).
Risk stratification was based on the Binet-classification:
Binet A (n=14), Binet B (n=6) or Binet C (n=1).
Cell Lines Included for Surface Marker Analyses
The following cell lines were studied for surface
marker profiles: HL-60 (AML-M2), OCI-AML2 (AML-
M4), Mono-Mac 6 (AML-M5), THP-1 (AML-M5),
MOLM (AML-M5a), RAMOS (B-ALL–L3), RAJI (B-
ALL–L3) and JURKAT (T-ALL). Cell lines were pur-
chased from the American Type Culture Collection and
were cultured according to the manufacturer’s instructions
(Table 2A).
AML Patients and Samples Included for Culture
Experiments
Cellular composition of immune reactive cells in MNC
or WB samples from 5 AML patients, 1 myelodysplastic
syndrome (MDS) patient and from 10 healthy volunteers
were studied before or after culture with/without DC/DCleu-
generating strategies or mixed lymphocyte culture (MLC)
with (T) cells from the patients. Details about patient and
sample characteristics are given in Table 2B.
Cell cultures were either performed under “normoxic
conditions” (371C, 5% CO2 and 21% O2). Further we
studied the influence of hypoxia on the composition and
function of different immune reactive cells and cultured
samples in parallel under “hypoxic conditions” (371C, 5%
CO2 and with either varying O2-concentrations between 0%
and 17% during the incubation time in some cases or
with a defined O2-concentration of 6% or 10%) using
an InVivo400 working station (Ruskinn Technology,
Bridgend, United Kingdom).
DC Generation From Isolated MNC or WB
DC/DCleu were generated from 4 to 510
6 isolated
MNC from healthy volunteers or AML/MDS patients in
blast-rich stages of the disease as described previously by
others or us19,27 using Kit-D, Picibanil 1 “(Pici1)” or “Pici2”
(Table 3) (D.C. Amberger, personal written communication).
Therefore, cells were pipetted into 12-multiwell tissue culture
plates (ThermoFisher Scientific, Darmstadt, Germany) and
were diluted in 2mL serum-free X-Vivo15-medium (Lonza,
Basel, Swiss).
Moreover, DC/DCleu were generated from WB
(presenting the physiological cellular and soluble composi-
tion of the individual samples) obtained from AML/MDS
patients in blast-rich stages of the disease or from healthy
volunteers.20,29 A total of 500 mL WB was pipetted in
12-multiwell plates and diluted 1:2 in X-Vivo15-medium to
imitate the physiological conditions. DC were generated
fromWB using 6 different DC-generating methods: “Pici1,”
“Pici2,” Kit-D, Kit-I, Kit-K, and Kit-M (Table 3). A patent
was written to save the idea of Kit-compositions
(102014014993.5, German Patent Office), but no financial
conflicts of interest have to be declared. In the subsequent
chapters we summarize all DC-generating methods and
Kits under the term “cocktails.” WB/MNC cultures with-
out added response modifiers severed as a control. All
substances used for the DC generation are approved for
human treatment.
DC-subtypes were quantified as described in the chapter
“Cell-characterization by flow cytometry”.19,20,29
“Pici1”
DC were generated from MNC or WB with the DC-
generating protocol “Pici1” containing 500U/mL gran-
ulocyte macrophage colony-stimulating factor (GM-CSF,
Sanofi-Aventis, Frankfurt, Germany) and 250U/mL
interleukin 4 (IL-4) (PeproTech, Berlin, Germany). After
6–7 days, 10 mg/mL Picibanil (OK 432)—a lysis product
from Streptococcus pyogenes which has unspecific immune
modulatory effects (Chugai Pharmaceutical Co., Kajiwara,
Japan) and 1mg/mL prostaglandin E2 (PGE2) (PeproTech)
were added.19,28 After 7–10 days of incubation cells were
harvested and used for further experiments.
“Pici2”
DC were generated from MNC or WB with the
“Pici2”-DC-generating protocol—a protocol developed by
our group, with the same composition as given above for
“Pici1,” however substituting PGE2 by PGE1 (PeproTech;
D.C. Amberger, personal communication).
Kit-D
The generation of DC from MNC or WB with Kit-D
was performed using 800U/mL GM-CSF, 10mg/mL Pici-
banil and 1 mg/mL PGE2.20 After 2–3 days the same
amounts of cytokines were added and after 7–10 days of
incubation cells were harvested and used for subsequent
experiments.
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TABLE 2. Patients’ and Cell-lines’ Characteristics are Presented
AML/ALL/CLL subtypes, age, sex, stages of the disease, proportions of blasts, blast phenotypes evaluated by flow cytometry are given.
1Complete remission (CR) achieved or not achieved (NCR) after treatment with SCT.
Bold letters antibodies used for (co)expression analyses.
ALL indicates acute lymphoid leukemia; AML, acute myeloid leukemia; BM, bone marrow; CIK, cytokine-induced killer; CLL, chronic
lymphoid leukemia; Dgn., first diagnosis; F, female; FAB, French American British classification; iNKT, invariant natural killer T; M, male;
NCCN, National Comprehensive Cancer Network; ND, no data; NK, natural killer; Pat.#, patient’s number; PB, peripheral blood; Pers., persisting
disease; Rel., relapse; Rel.a.SCT, relapse after stem cell transplantation.
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Kit-I
DC were generated with Kit-I using 800U/mL
GM-CSF and 10 mg/mL Picibanil.20 Incubations were per-
formed in analogy to Kit-D.
Kit-K
Kit-K consisted of 800U/mL GM-CSF and 1mg/mL
PGE2.
20 Incubations were performed in analogy to Kit-D.
Kit-M
For the generation of DC with Kit-M, 800U/mL GM-
CSF and 1 mg/mL PGE1 were added to the culture.20
Incubations were performed in analogy to Kit-D.
MLC of T-Cell–Enriched Immune Reactive Cells With
“Cocktails” Pretreated or Not Pretreated Stimulator
Cell Suspensions From MNC or WB
Immune reactive cells were enriched with 1106 pos-
itively selected CD3+ T cells (effector cells) from AML
patients or healthy controls and cocultured in 24-multiwell
tissue culture plates (ThermoFisher Scientific) with a stim-
ulator cell suspension containing 2.5105 DC/DCleu
(MLC*“MNC-DC” or MLC*“WB-DC” which were generated
with different “cocktails.” The same setting, but with a
stimulatorcell suspension without pretreatment with
“cocktails” (MLC*“MNC” or MLC*“WB”) severed as a
control. In 1 parallel tested case the stimulator cell sus-
pensions were irradiated with 33Gy to inactivate residual
immune reactive cells (eg, iNKT/NK and CIK cells). The
total volume of the cell culture was adjusted to 1mL with
RPMI-1640 medium (Biochrom) containing 1% Penicillin
(Biochrom) and 50U/mL IL-2 (PeproTech). The
MLC*“MNC” or MLC*“MNC-DC” further contained 15%
human serum (Healthcare Europe GmbH, Vienna, Aus-
tria). After 2–3 days 50U/mL IL-2 were added to the WB
and MNC cultures. Half medium exchange for MNC cul-
tures was carried out every 2–3 days. Cells were harvested
after 6–9 days and were used for the cytotoxicity-fluorolysis
assay as described below.
Before and after culture different cell subsets in the
MNC-fraction and WB-fraction were quantified by flow
cytometry (Table 1).
Enzyme-linked Immunosorbent Assay (ELISA)
Cell culture supernatants after AML-WB-DC culture
stimulated with different “cocktails” (“Pici1,” “Pici2,”
Kit-D, Kit-I, Kit-K, and Kit-M) and after MLC*“WB-DC”
(n=4) were analyzed for IL-10, IL-17, Monocyte
Chemoattractant Protein-1 (MCP-1) and interferon gamma
(IFN-g) secretion using the human IL-10, IL-17A, MCP-1,
and IFN-g immunoassay kits (DRG Instruments GmbH,
Marburg, Germany). Moreover, WB-DC cultures without
added response modifiers and MLC*“WB” severed as a
control. The samples were evaluated with a Tristar LB941
ELISA reader (Berthold company, Bad Wildbach, Ger-
many) and the concentration of the 4 different cytokines
evaluated using the corresponding standard curve.
Cell Characterization by Flow Cytometry
Flow cytometric analyses were carried out to evaluate
and quantify amounts, subsets and phenotypes of leukemic
cells, B, T, iNKT, NK, and CIK cells, monocytes and DC
in the MNC and WB fractions before and after different
cultures. Panels with several moAbs labeled with fluo-
rescein isothiocyanat (FITC), phycoerythrin (PE), tandem
Cy7-PE conjugation (Cy7-PE), or allophycocyanin (APC)
were used. Antibodies were provided by Beckman Coulter,
Krefeld, Germany (a); Becton Dickinson, Heidelberg,
Germany (b); Biozol, Eching, Germany (c); Caltag, Darm-
stadt, Germany (d); Bioscience, Heidelberg, Germany (e);
Miltenyi Biotech, Bergisch Gladbach, Germany (f); and
ThermoFisher Scientific (g). FITC-conjugated moAbs
against CD3a, CD8b, CD33a, CD34a, CD45ROa, CD83a,
CD161b, 6B11c, and Va24a were used. We used PE-
conjugated moAbs for CD1de, CD3a, CD4b, CD34a,
CD80a, CD83a, CD117a, CD206a, and 6B11b. MoAbs
against CD3a, CD4a, CD5a, CD14b, CD15b, CD19a,
CD34a, CD80b, CD117a, and CD197b were labeled with
Cy7-PE. As APC-labeled moAbs we used CD1aa, CD3a,
CD4a,b, CD5a, CD7e, CD8b, CD10a, CD14a, CD15b,
CD19a, CD20a, CD33a, CD34a,d, CD45ROd, CD56a,
CD69b, CD86g, CD117a, CD133f, CD206b, and CD209b.
To detect dead cells 7AADb was used.
Erythrocytes in WB samples were lysed using Lysing-
Buffer (BD, Heidelberg, Germany) according to the man-
ufacturer’s instructions. To stain cells (MNC or WB) with
moAbs they were resuspended in PBS (Biochrom), con-
taining 5%–10% fetal calf-serum (Biochrome) to avoid
unspecific bindings and were incubated for 15 minutes in
the dark at room temperature. Afterwards cells were
washed, centrifuged, and resuspended in 100–200mL PBS.
At least 5000 events were evaluated with a fluorescence-
activated cell-sorting Flow Cytometer (FACSCalibur) and
TABLE 3. Overview of the Different DC-generating Methods/Kits
(“Cocktails”)19,20,28







































*Personal communication D.C. Amberger.
DC indicates dendritic cells; GM-CSF, granulocyte macrophage colony-
stimulating factor; IL-4, interleukin 4; OK-432, Picibanil; PGE1, prosta-
glandin E1; PGE2, prostaglandin E2.
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Cell-Quest data acquisition and analysis software (Becton
Dickson, Heidelberg, Germany). Isotype controls were
conducted according to the manufacturer’s instructions.
For the analysis and quantification of T, iNKT, NK,
and CIK cells/subtypes were quantified in the total cell-
fraction (eg, CD3+ cells) or in the subpopulations (eg,
6B11+CD3+). According to their expression profile we
quantified proportions of immune reactive cells as given
in Table 1: T cells: CD3+, CD8+, CD4+, Va24+,
CD1d+ T-cells, Tnaive, Tnon-naive, Tcm or Teff-em.
9,10,13 CIK
cells: CD3+CD56+ or CD3+CD161+ cells. NK cells:
CD3CD56+ or CD3CD161+ cells.5,13 (6B11+) iNKT
cells: 6B11+CD3+, 6B11+CD161+, 6B11+Va24+,
6B11+CD4+, 6B11+CD8+, 6B11+CD1d+, 6B11+
CD45RO+ or 6B11+CD45RO iNKT cells. Exemplarily,
dot plots iNKT, NK, and CIK cells and the gating strategy
of iNKT cells/subsets are given in Figure 1. Moreover,
aberrant expressions of CD161 and 6B11 on blasts were
studied (Table 1).13
For the analysis and quantification of DC/DCleu
subtypes in the total cell fraction or in subtype cell fraction
after DC culture in the MNC or WB fraction (DCleu/cells)
we used a refined gating strategy6,8: subgroup analyses were
conducted only in cases with Z10% DC. DCleu were
quantified in the total fraction (DCleu/cells) in the DC
fraction (DCleu/DC) or in the blast fraction, to quantify
the amount of blasts converted to DCleu (DCleu/bla),
mature DC (coexpressing the migration marker CCR7) and
viable DC (negative for 7AAD) were quantified in the DC
fraction after culture (DCmig/DC; DCvia/DC, Table 1,
1.1. Dot plots of NK-, CIK-, iNKT-cells in healthy or AML-MNC
 NK-and CIK-cells in healthy-(left side) or AML-MNC (right side) 
iNKT-cells in healthy-(left side) or AML-MNC (right side)







FIGURE 1. Gating strategy and corresponding dot plots of CIK, NK and iNKT cells in healthy or AML MNC are given. 1.1. Various
frequencies of NK (CD3CD56+) and CIK cells (CD3+CD56+) in healthy or AML MNC are given (A). Various frequencies of iNKT cells
(6B11+CD3+ and 6B11+CD3) in healthy or AML MNC are given (B). 1.2. Gating of 6B11+ cells and characterization of corresponding
subsets (6B11+CD3+CD161+ , 6B11+CD3CD161+) are given. ALL indicates acute lymphoid leukemia; AML, acute myeloid leukemia;
CIK, cytokine-induced killer; MNC, mononuclear cells; NK, natural killer; iNKT, invariant natural killer T. R1 = gate surrounding all
6B11 + cells in the AML-MNC fraction.
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lower part). For this purpose, cells were stained with
patient-specific “blast”-staining antibodies (eg, CD15,
CD34, CD65, and CD117) according to diagnostic reports
before culture in combination with “DC”-staining anti-
bodies (eg, CD80, CD83, CD86, CD206, and CD209),
which were not expressed before culture.
Cytotoxicity (Fluorolysis) Assay
To analyze the blast lytic activity of T-cell–enriched
immune reactive cells after MLC with “cocktails”-pretreated
or not pretreated stimulator cell suspensions from MNC or
WB a fluorolysis assay was performed.19 Therefore, effector
cells (E) were cocultured 1:1 with thawed blast-containing
target cells (T) for 3 and 24 hours at 371C, with 21% O2 and
5% CO2. As a control effector cells and target cells were
cultured for the same time separately and mingled on ice
shortly before the flow cytometric analyses were carried out.
Before culture, target cells were stained for 15 minutes with
FITC, PE or APC-conjugated blast, monocyte or T cell-specific
target cell antibodies. To evaluate viable cells and the lytic
activity of effector cells, the cultures were harvested after 3 and
24 hours and resuspended in PBS containing 7AAD (Becton
Dickson) and a defined number of Fluorospheres beads
(Beckman Coulter). For analyses, a refined gating was used.8
Therefore, viable target cells were gated in a FSC/7AAD
gate. With a FACS Calibur Flow Cytometer and a Cell-Quest
software (Becton Dickson) cells were analyzed. The lytic
activity was calculated and defined as the difference in the
percentage of viable target blasts before and after the effector
cell contact.
Statistical Methods
Data were presented as mean±SD. Statistic compar-
isons for 2 groups were performed using the t test and Mann-
Whitney-Wilcoxon test. The statistical analysis was done with
Microsoft Excel 2010 or 2013 (Microsoft, Redmond, WA)
and JMP10.0 statistical software (SAS Institute, Cary, NY).
Differences were considered as “not significant” (ns) with
P-values >0.1, as “borderline significant” (significant*) with
P-values between 0.1 and 0.05, as “significant” (significant**)
with P-values between 0.05 and 0.005 and as “highly sig-
nificant” (significant***) with P-values <0.005.
RESULTS
Prolog
During the development of acute and chronic leuke-
mia B, T lymphocytes and monocytes are displaced by
increasing blast cell-populations. In our samples between
8% and 99% of blast cells and varying proportions of the
remaining hematopoietic cells were detectable. Details of
the cellular composition of AML/ALL/CLL samples are
shown in Table 4. Samples with blasts, that aberrantly
expressed CD3, CD4, CD8, CD14 or CD19, were excluded
from quantification analyses for the respective lineage markers.
In our first approach, we compared frequencies and
compositions of iNKT, NK, CIK cells as well as T cell
subtypes in (unstimulated) MNC from healthy donors with
AML, ALL and CLL patients and correlated findings with
prognosis of these patients. Moreover, we studied potential
(aberrant) coexpressions of iNKT markers on leukemic cell
lines. In our second approach we analyzed proportions of
AML blasts and immune reactive cells (with a special focus
on iNKT, NK, and CIK cells) and their expression profiles
after MLC.
The 6B11-antibody, targeting the invariant CDR3
loop of the Va24Ja18 TCR, is regarded as a specific anti-
body to detect iNKT cells. In our experiments, we used
2 different antibodies: 6B11 (clone 6B11) labeled with
PE (6B11-PE, delivered by BD) and 6B11 (clone 6B11)
labeled with FITC (6B11-FITC, delivered by Biozol). First
comparative analyses with these markers in MNC from
AML, ALL, CLL patients revealed significantly* higher
proportions of iNKT cells detected with the 6B11-
FITC compared with 6B11-PE (AML: 1.52%±1.74%
vs. 0.75%±1.10%, P<0.0652; ALL: 1.24%±1.52% vs.
0.74%±0.64%, P<0.103; CLL: 0.92%±0.87% vs.
0.78%±0.47%, P<0.299). However, proportions of
iNKT cells detected with 6B11-FITC were significantly**
lower in healthy samples compared with leukemic samples
(AML: 0.40%±0.26% vs. 1.52%±1.74%, P<0.01073;
ALL: 0.40%±0.26% vs. 1.24%±1.52%, P<0.01622;
CLL: 0.40%±0.26% vs. 0.92%±0.87%, P<0.02267),












AML T cells (CD3+) 6 1–33




Blasts (B or T
lineage blasts)
71 17–99
ALL T cells (CD3+)* 14 5–33











T cells (CD3+) 41 24–64








4.2. AML and healthy samples used for culture experiments
Blasts 28/17 8–60/15–18
AML T cells (CD3+) 21/11 2–54/5–17




T cells (CD3+) 18/35 14–21/9–48




*Only quantified in B lineage ALL.
wOnly quantified in T lineage ALL.
ALL indicates acute lymphoid leukemia; AML, acute myeloid leukemia;
CLL, chronic lymphoid leukemia; MNC, mononuclear cells; WB, whole
blood; Ø, mean.
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while iNKT cells detected with 6B11-PE were significantly*
higher in healthy samples compared with leukemic samples
(AML: 2.47%±3.12% vs. 0.75%%±1.10%, P<0.081;
ALL: 2.47%±3.12% vs. 0.74%±0.65%, P<0.083;
CLL: 2.47%±3.12% vs. 0.78%±0.47%, P<0.0827).
We decided for better comparibility to present only data
obtained with 6B11-PE.
We evaluated 8 different leukemic cell lines (HL-60,
OCI-AML2, THP-1, Mono-Mac-6, MOLM-13, RAMOS,
RAJI, JURKAT) to analyze if 6B11 or CD161 is aberrantly
expressed on blasts. We could demonstrate that neither
CD161 nor 6B11 were (aberrantly) expressed on blasts of
leukemic myeloid and B lineage cell lines with a mean coex-
pression on blasts of 2.59%±0.02% or 2.67%±0.03%.
However, 8.38% 6B11+bla+ and 10.03% CD161+bla+
cells were found in the T-linear Jurkat cell line. Moreover, we
could demonstrate that neither CD161 nor 6B11 were aber-
rantly expressed on leukemic blasts obtained from patients
with AML, ALL or CLL. On average, coexpression of
CD161 and 6B11 on blasts was: AML: 0.23%±0.01% or
0.35%±0.01%; ALL: 0.55%±0.01% or 0.66%±0.01%;
CLL: 0.17%±0.00% or 1.60%±0.01%.
Therefore, analyzing iNKT cells with 6B11-PE and
NK/CIK cells with CD161 represent specific results as 6B11
and CD161 antibodies do not show unspecific bindings on
blasts, although combinations of (fluorochrome)-labeled
antibodies have to be tested thoroughly.
moAbs and their Combinations for iNKT, NK,
and CIK Cell/Subtype Analyses
For iNKT cell detection in healthy and AML, ALL, and
CLL samples, we used moAb 6B11 alone or in combination
with CD3, CD161, Va24, CD1d, CD45RO, CD4, and CD8.
We defined iNKT cells detected with 6B11 in combination with
T cell markers (CD3, Va24, CD1d, CD45RO, CD4, and CD8)
as “T cell-like” iNKT cells and iNKT cells detected with 6B11
in combination with NK cell markers (CD161) as “NK cell-
like” iNKT cells. The frequencies of iNKT cells detected with
6B11 alone were similar in AML, ALL, and CLL patients
(0.75%±1.10% vs. 0.74%±0.65% vs. 0.78%±0.47%).
Frequencies of iNKT cells detected with 6B11 in combina-
tion with CD3 (6B11+CD3+/MNC) were slightly lower in
AML, ALL, and CLL patients (0.58%±1.15% vs.
0.61%±0.42% vs. 0.46%±0.47%), but the percentages were
comparable to results with 6B11 in combination with CD1d
(6B11+CD1d+/MNC, 0.66%±1.16% vs. 0.66%±0.96%
vs. 0.48%±0.64%). Proportions of 6B11+CD161+/MNC
iNKT cells were even smaller in AML, ALL, and CLL patients
(0.14%±0.25% vs. 0.18%±0.16% vs. 0.22%±0.26%),
while 6B11+ Va24 +/MNC could only detect very few fre-
quencies of iNKT cells (0.09%±0.10% vs. 0.08%±0.18%
vs. 0.03%±0.03%). We could show higher frequencies of
6B11+CD4+/MNC versus 6B11+ CD8+/MNC iNKT
cells detected in AML, ALL, and CLL patients (CD4+ iNKT
cells: 0.18%±0.20% vs. 0.32%±0.33% vs. 0.25%±0.12%;
CD8+ iNKT cells: 0.03%±0.04% vs. 0.07%±0.09% vs.
0.06%±0.05%). Moreover, we could show that the majority
of 6B11+iNKT cells express CD45RO in AML, ALL, and
CLL patients (88.58%±14,43% vs. 79.75%±30.00% vs.
64.58%±29.53%).
In conclusion, frequencies of iNKT cells and their sub-
sets can be detected with 6B11 alone (PE-labeled clone pre-
ferred) or in combination with CD3, CD161, CD1d or Va24.
The combination of 6B11 with CD4, CD8, and CD45RO can
be used for further subset-analyses of iNKT cells.
Frequencies and Compositions of iNKT, NK, and
CIK Cells From AML Patients Compared With
Healthy Controls and their Correlation With
Prognosis
AML Patients Show Significantly Lower Proportions
of iNKT, NK, and CIK Cells in MNC Compared With
Healthy MNC
We found significantly*** lower frequencies of CD3+
CD56+ CIK cells in MNC of AML patients compared with
healthyMNC (0.46%±0.62% vs. 2.74%±1.64%, P<0.0021)
and significantly*** lower percentages of CD3+CD161+
CIK cells (0.30%±0.40% vs. 3.25%±1.02%, P<0.000152,
Fig. 2A). In addition, we could show significantly*** lower
proportions of CD3CD56+ NK cells (1.68%±1.97% vs.
9.33%±4.06%, P<0.00064) and significantly** lower pro-
portions of CD3CD161+ NK cells in MNC of AML
patients compared with healthy MNC (1.01%±1.26% vs.
2.44%±1.20%, P<0.0142, Fig. 2B). We could demons-
trate significantly* lower percentages of 6B11+ iNKT cells
(0.75%±1.10% vs. 2.47%±3.12%, P<0.081) and (ns) lower
proportions of 6B11+CD3+ and 6B11+CD161+iNKT cells
in MNC of AML patients compared with healthy MNC
(Fig. 2C). Moreover, 6B11+CD8+ and 6B11+Va24+ iNKT
cells were found in lower proportions in MNC from AML
patients versus healthy MNC [data not shown (dns)].
In summary frequencies of 6B11+/6B11+CD3+/
6B11+CD161+/6B11+CD8+/6B11+Va24+ iNKT, CD3
CD56+/CD3CD161+ NK, and CD3+CD56+/CD3+
CD161+ CIK cells/subsets were (significantly) lower in MNC
from AML patients than in healthy MNC.
(Significantly) Higher Proportions of T and NK Cells
Express 6B11 in AML Patients Compared With
Healthy Controls
We found significantly*** increased proportions of CD3+
T cells expressing 6B11 in AML patients compared with healthy
controls (14.03%±14.66% vs. 2.69%±2.17%, P<0.00111,
Fig. 2D). Moreover, we found significantly** higher frequencies
of CD4+ (8.36%±15.22% vs. 0.31%±0.38%, P<0.0123)
and CD161+ cells expressing 6B11 (17.19%±15.36% vs.
4.62%±5.97%, P<0.0152, Fig. 2D) and significantly*
increased frequencies of CD8+ cells expressing 6B11 in MNC
of AML patients versus healthy controls (1.89%±3.55% vs.
0.59%±1.12%, P<0.0723). We did not find significant
differences of CD3+CD161+ CIK cells in the CD3+ T cell
fraction of AML patients compared with CD3+CD161+ CIK
cells in the healthy T cell fraction (dns).
In summary a shift to higher proportions of (CD3+/
CD4+/CD8+) T cells and (CD161+) NK cells coex-
pressing 6B11 was found in AML patients compared with
healthy samples. No differences of CD3+CD161+ CIK
cells in the CD3+ T-cell fraction were observed.
AML Patients With Prognostically Favorable
Subgroups are Characterized by Higher Proportions of
iNKT, NK, and CIK Cells
AML patients who achieved CR after induction che-
motherapy were characterized by significantly** higher
frequencies of CD3+CD56+ CIK cells in MNC-fractions
than AML patients with no complete remission (NCR;
0.4%±0.33% vs. 0.05%±0.05%, P<0.0094, Fig. 5.1A,
left side), whereas proportions of NK or iNKT cells were
not different in MNC fractions of patients who achieved
versus not achieved a CR (dns). AML-patients with
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favorable versus adverse NCCN risk-score presented with
(ns) higher values of 6B11+-iNKT cells in the MNC-
fraction (0.64%±0.11% vs. 0.56%±0.09%; Fig. 5.1A,
middle row). Comparable results were found for 6B11+
Va24+ and 6B11+CD161+ iNKT cell-proportions in the
MNC-fraction of AML-patients with favorable versus
adverse NCCN risk-score (dns).
AML-patients younger than 60 years presented with (ns)
higher frequencies of 6B11+iNKT cells in the MNC-fraction
compared with AML-patients older than 60 years
(0.89%±1.35% vs. 0.53%±0.40%, Fig. 5.1A, right side).
Comparable results were found for 6B11+CD3+ and
6B11+CD161+ iNKT cell proportions in the MNC-fraction
of AML-patients younger than 60 years versus older than 60
years (dns). No differences were found for proportions of NK
or CIK cells in the groups compared (dns).
AML-patients with primary versus secondary AML pre-
sented with (ns) higher frequencies of 6B11+ and 6B11+
CD3+ iNKT cells in the MNC-fraction (0.78%±1.21% vs.
0.62%±0.46%; 0.66%±1.29% vs. 0.32%±0.23%). No
differences were found for proportions of NK or CIK cells in
the groups compared (dns).
AML-patients without extramedullary foci (n=20) com-
pared with those with extramedullary foci (n=3) presented with
significantly*** increased proportions of CD3+CD56+CIK
































































































FIGURE 2. Frequencies of CIK, NK and iNKT cells and their subsets in healthy versus AML MNC are given. Percentages of CIK cells
(CD3+CD56+/MNC and CD3+CD161+/MNC) (A), NK cells (CD3CD56+/MNC and CD3CD161+/MNC) (B), iNKT cells in MNC
(6B11+ , 6B11+CD3+/MNC, 6B11+CD161+/MNC) (C), and iNKT cell subsets in the T cell fraction (6B11+CD3+/CD3+) and in the NK
cell fraction (6B11+CD161+/CD161+) (D) are given. ALL indicates acute lymphoid leukemia; AML, acute myeloid leukemia; CIK,
cytokine-induced killer; MNC, mononuclear cells; NK, natural killer; iNKT, invariant natural killer T.
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P<0.0023; Fig. 5.1B left side). Moreover, the percentages of
CD3CD56+ NK cells was significantly*** higher in cases
without compared with patients with extramedullary foci
(1.97%±0.21% vs. 0.08%±0.04%, P<0.0017, Fig. 5.1B,
middle row) Furthermore we found (ns) higher frequencies of
6B11+ iNKT cells in the MNC fraction of AML-patients
without versus with extramedullary foci (0.81%±1.16% vs.
0.37%±0.24%; Fig. 5.1B right side). Comparable results were
found for 6B11+CD3+ and 6B11+CD161+iNKT cell-
proportions in the MNC-fraction in the groups compared (dns).
AML-patients who stayed in stable CR versus no stable
CR (NCR) showed (ns) higher frequencies of CD3+CD161+
CIK cells and CD3CD161+ NK cells in the MNC-fraction
(0.47%±0.58% vs. 0.16%±0.08%; 1.21%±1.73% vs.
0.90%±072%; Fig. 5.1C left side, middle row). Moreover, we
found (ns) higher percentages of 6B11+iNKT cells in the
MNC-fraction of AML-patients who stayed in stable CR
versus NCR (1.04%±1.63% vs. 0.37%±0.10%; Fig. 5.1C,
right side). Comparable results were found for 6B11+CD3+
and 6B11+CD161+ iNKT cell proportions in the MNC
fraction in the groups compared (dns).
In summary in AML-patients (significantly) higher
proportions of 6B11+iNKT cells correlated with favorable
NCCN risk-score, younger age, primary AML, no extra-
medullary foci and stable CR. Similar correlations were
found for 6B11+CD3+/6B11+CD161+ and 6B11+
Va24+iNKT-subsets. High frequencies of CD3CD56
NK cells and CD3+CD56+ CIK cells NK and CIK cells
correlated significantly with no extramedullary foci.
Moreover, higher proportions of CD3CD161+ NK cells
and CD3+CD161+CIK cells correlated with stable CR in
AML-patients and CD3+CD56+ CIK cells correlated
with the achievement of CR after induction chemotherapy
in AML-patients.
Frequencies and Subtypes of iNKT, NK, and CIK
Cells From ALL-Patients Compared With Healthy
Controls and their Correlation With Prognosis
ALL-Patients Show Significantly Lower Proportions
of iNKT, NK, and CIK Cells in MNC Compared With
Healthy MNC
We found significantly** lower frequencies of CD3+
CD56+CIK cells in MNC of ALL-patients compared
with healthy MNC (1.36%±1.63% vs. 2.74%±1.64%,
P<0.0395) and significantly*** lower percentages of CD3+
CD161+CIK cells (0.94%±1.45% vs. 3.25%±1.02%,
P<0.00039, Fig. 3A). Moreover, we found significantly***
lower proportions of CD3CD56+NK cells (2.68%±2.35%
vs. 9.33%±4.06%, P<0.00163) and significantly*** lower
proportions of CD3CD161+NK cells inMNC of ALL-patients
versus healthy MNC (0.52%±0.92% vs. 2.44%±1.20%,
P<0.00344, Fig. 3B). We could show significantly* lower
frequencies of 6B11+iNKT cells in MNC of ALL-patients
versus healthy MNC (0.74%±0.65% vs. 2.47%±3.12%,
P<0.083, Fig. 3C). Moreover, 6B11+CD3+/6B11+CD8+/
6B11+CD161+ and 6B11+Va24+iNKT cells were found in
(ns) lower proportions in MNC from ALL-patients versus healthy
MNC (dns).
In summary frequencies of 6B11+/6B11+CD3+/
6B11+CD161+/6B11+CD8+/6B11+Va24+ iNKT,
CD3CD56+/CD3CD161+ NK, and CD3+CD56+/
CD3+CD161+ CIK cells/subsets were (significantly)
lower in ALL-MNC than in healthy MNC.
(Significantly) Higher Proportions of T and NK Cells
Express 6B11 in ALL-Patients Compared With
Healthy Controls
We found significantly* lower percentages of CD3+
CD161+ CIK cells in the CD3+ T-cell fraction of ALL-patients
compared with CD3+CD161+CIK cells in the healthy CD3+
T-cell fraction (5.25%±7.17% vs. 8.92%±2.82%, P<0.053),
but significantly** higher proportions of CD3+ T cells
expressing 6B11 in ALL-patients compared with healthy controls
(6.03%±5.25% vs. 2.69%±2.17%, P<0.0102, Fig. 3D).
Furthermore, we found significantly** higher frequencies of CD4+
(7.27%±11.04% vs. 0.31%±0.38%,P<0.00745) and CD161+
cells expressing 6B11 (15.63%±16.46% vs. 4.62%±5.97%,
P<0.0057, Fig. 3D) and significantly* higher percentages of
CD8+cells expressing 6B11 in ALL patients versus healthy controls
(1.28%±1.44% vs. 0.59%±1.12%, P<0.081).
In summary a shift to higher proportions of (CD3+/
CD4+/CD8+) T cells and (CD161+) NK cells coex-
pressing 6B11 was found in ALL-patients compared with
healthy samples. However, unlike in AML-patients, lower
frequencies of CD3+CD161+CIK cells were found in the
CD3+ T-cell fraction of ALL-patients versus in the healthy
CD3+ T-cell fraction.
Adult ALL-Patients With Prognostically Favorable
Subgroups are Characterized by Higher Proportions of
iNKT and NK Cells
The ALL-patients’ cohort included children and adults.
As only 1 child relapsed only adult ALL-patients (treated with
GMALL-therapy) were included in prognostic analyses.
Adult ALL-patients who achieved a CR after GMALL-
induction chemotherapy were characterized by (ns) higher
frequencies of CD3CD161+NK cells in MNC fractions than
ALL-patients who achieved without CR (1.09%±1.48% vs.
0.18%±0.11%, dns). Moreover, we found (ns) higher percen-
tages of 6B11+, 6B11+CD3+, and 6B11+Va24+ iNKT cells
in the MNC-fraction of ALL-patients who achieved CR versus
NCR (0.95%±1.02% vs. 0.65%±0.37%; 0.61%±0.34%
vs. 0.58%±0.26%; 0.16%±0.30% vs. 0.03%±0.05%, dns).
No differences were found for CIK cells.
Adult ALL-patients without extramedullary foci
compared with those with extramedullary foci presented
with (ns) higher proportions of 6B11+, 6B11+CD3+,
and 6B11+Va24+ iNKT cells in the MNC fraction
(1.12%±1.07% vs. 0.54%±0.30%; 0.63%±0.38% vs.
0.56%±0.21%; 0.20±0.32% vs. 0.02%±0.02%, dns).
No differences were found for NK and CIK cells.
Although only few data were available we can demon-
strate, that higher proportions of 6B11+/6B11+CD3+/
6B11+Va24+ iNKT cells correlate with adult ALL-patients
who achieved CR and without extramedullary foci. Moreover,
CD3CD161+ NK cells correlated with adult ALL-patients
who achieved CR. no correlations were found for CIK cells.
Frequencies and Subtypes of iNKT, NK,
and CIK Cells From CLL Patients Compared
With Healthy Controls and Correlations With
Prognosis
CLL-Patients Show Significantly Lower Proportions
of iNKT, NK, and CIK Cells in MNC Compared With
Healthy MNC
We found significantly*** lower frequencies of CD3+
CD56+ CIK cells in MNC of CLL-patients compared
with healthy MNC (0.67%±0.73% vs. 2.74%±1.64%,
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P<0.0036) and significantly*** lower frequencies of CD3+
CD161+ CIK cells (0.67%±0.84% vs. 3.25%±1.02%,
P<0.000168, Fig. 4A). Moreover, we found significantly***
lower proportions of CD3CD56+ NK cells (3.27%±3.26% vs.
9.33%±4.06%, P<0.00243) and significantly*** lower pro-
portions of CD3CD161+ NK cells in MNC of CLL-patients
versus healthy MNC (0.45%±0.48% vs. 2.44%±1.20%,
P<0.00302, Fig. 4B). Moreover, we found significant* lower
frequencies of 6B11+ (0.78%±0.47% vs. 2.47%±3.12%,
P<0.0828), 6B11+CD3+ (0.46%±0.47% vs. 0.93%±0.72%,
P<0.072, Fig. 4C) and 6B11+Va24+ iNKT cells in MNC
of CLL patients versus healthy MNC (0.03%±0.03% vs.
0.16%±0.27%, P<0.09522). Moreover, lower proportions of
6B11+CD8+ and 6B11+CD161+ iNKT cells were found in
MNC from CLL patients versus healthy MNC (dns).
In summary frequencies of 6B11+/6B11+CD3+/6B11+
CD161+/6B11+CD8+/6B11+Va24+ iNKT, CD3CD56+/
CD3CD161+ NK and CD3+CD56+/CD3+CD161+ CIK
cells/subsets were (significantly) lower in CLL MNC than in
healthy MNC.
Significantly Higher Proportions of T and NK Cells
Express 6B11 in CLL-Patients Compared With
Healthy Controls
We found significantly*** higher frequencies of CD3+

































































































FIGURE 3. Frequencies of CIK, NK and iNKT cells and their subsets in healthy versus ALL MNC are given. Percentages of CIK cells
(CD3+CD56+/MNC and CD3+CD161+/MNC) (A), NK cells (CD3CD56+/MNC and CD3CD161+/MNC) (B), iNKT cells in MNC
(6B11+ , 6B11+CD3+/MNC, 6B11+CD161+/MNC) (C), and iNKT cell subsets in the T cell fraction (6B11+CD3+/CD3+) and in the NK
cell fraction (6B11+CD161+/CD161+) (D) are given. ALL indicates acute lymphoid leukemia; CIK, cytokine-induced killer; MNC,
mononuclear cells; NK, natural killer; iNKT, invariant natural killer T.
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healthy controls (11.27%±11.83% vs. 2.69%±2.17%,
P<0.00384, Fig. 4D). Furthermore, we found significantly**
higher frequencies of for CD4+ cells expressing 6B11
(7.14%±5.90% vs. 0.31%±0.38%, P<0.00908) and
significantly*** higher frequencies of CD161+ cells expre-
ssing 6B11 in CLL-patients versus healthy controls
(23.55%±20.47% vs. 4.62%±5.97%, P<0.00043, Fig. 4D).
We did not find significant differences in the numbers of
CD3+CD161+ CIK cells in the CD3+ T cell fraction and
CD8+ T cells expressing 6B11 (dns).
In summary a shift to higher proportions of (CD3+/
CD4+) T cells and (CD161+) NK cells coexpressing 6B11
was found in CLL-patients compared with healthy samples.
Like in AML patients, but unlike in ALL patients, no
differences were found for CIK cells in the CD3+ T-cell
fraction. Unlike AML and ALL patients no differences
were found for CD8+ T cells expressing 6B11.
CLL-Patients With Prognostically Favorable
Subgroups are Characterized by Higher Proportions of
iNKT, NK, and CIK Cells
CLL-patients with no need versus need for therapy
presented with significantly* higher proportions of CD3+
CD56+ CIK cells in the MNC fraction (1.07%±1.03% vs.
0.43%±0.28%, P<0.093; Fig. 5.2A, left side). We found
(ns) higher frequencies of 6B11+ iNKT cells in the MNC
fraction of CLL patients with no need versus need for ther-
apy (0.81%±0.50% vs. 0.73%±0.40%; Fig. 5.2A, middle
row). Comparable results were found for 6B11+CD3+ and



































































































FIGURE 4. Frequencies of CIK, NK, and iNKT cells and their subsets in healthy versus CLL MNC are given. Percentages of CIK cells
(CD3+CD56+/MNC and CD3+CD161+/MNC) (A), NK cells (CD3CD56+/MNC and CD3CD161+/MNC) (B), iNKT cells in MNC
(6B11+ , 6B11+CD3+/MNC, 6B11+Va24 +/MNC) (C), and iNKT cell subsets in the T-cell fraction (6B11+CD3+/CD3+) and in the NK
cell fraction (6B11+CD161+/CD161+) (D) are given. CIK indicates cytokine-induced killer; CLL, chronic lymphoid leukemia; MNC,
mononuclear cells; NK, natural killer; iNKT, invariant natural killer T.
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of CLL patients with no need versus need for therapy (dns).
No differences were found for NK cells.
CLL-patients younger versus older than 60 years
presented with significantly* higher frequencies of 6B11+
and 6B11+Va24+ iNKT cells in the MNC fraction
(0.87%±0.55% vs. 072%±0.40%; 0.04%±0.03% vs.
0.01%±0.01%; P<0.0711, Fig. 5.2A, right side).
CLL-patients with stable versus no stable disease (NCR,
relapse or death with disease) presented with (ns) higher per-
centages of CD3+CD56+ CIK cells and CD3CD56+ NK
cells in MNC fraction (0.70%±0.79% vs. 0.47% ±0.23%;
3.40%±3.33% vs. 3.50%±2.64%, Fig. 5.2B, left side;
middle row). Moreover, we could demonstrate sig-





































5.1. Prognostic relevance for AML-pts
A   Response to chemotherapy (CR vs NCR, left side), allocation to favorable vs adverse 
      risk score (NCCN, middle row), allocation to age groups (<60 vs > 60 years, right side)
B  Extramedullary vs no extramedullary foci
C  Stable CR (yes or no) 
5.2. Prognostic relevance for CLL-pts
A  Need for therapy (yes or no, left side + middle row), allocation to age groups (<60 vs 
      >60 years, right side)

































































































FIGURE 5. Relevance of CIK, NK, and iNKT cells and their subsets for prognosis of AML and CLL patients. 5.1. AML patients: Frequencies
of CIK cells in patients with CR versus NCR after induction chemotherapy, iNKT cells in patients with favorable versus adverse risk score
(NCCN) and younger than 60 versus older than 60 years (A), CIK, NK, and iNKT cells in patients with extramedullary versus no
extramedullary foci (B), and CIK, NK, and iNKT cells in patients with stable versus no stable disease are given (C). 5.2. CLL patients:
frequencies of CIK and iNKT cells in patients with no need versus need for therapy, iNKT cells in patients younger than 60 versus older
than 60 years (A) and CIK, NK, and iNKT cells in patients with stable versus no stable disease are given (B). AML indicates acute myeloid
leukemia; CIK, cytokine-induced killer; CLL, chronic lymphoid leukemia; CR, complete remission; iNKT, invariant natural killer T; MNC,
mononuclear cells; NCCN, National Comprehensive Cancer Network; NCR, no complete remission; NK, natural killer; pts, patients.
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vs. 0.47%±0.06%, P<0.021, Fig. 5.2B) and significantly*
higher frequencies of 6B11+CD3+ iNKT cells in the MNC
fraction of CLL patients with stable CR versus NCR
(0.49%±0.48% vs. 0.17%±0.09%, P<0.0597 right side).
In summary (significantly) higher proportions of
6B11+ iNKT cells correlated with no need for therapy,
CLL patients younger than 60 years and stable CR. Com-
parable correlations were found for 6B11+CD3+/
6B11+Va24+ iNKT subsets. CD3CD56+ NK and
CD3+CD56+ CIK cells regularly correlated with stable
CR, while only CD3CD56+ NK cells correlated with no
need for therapy.
iNKT, NK, and CIK Cells and their Subtypes
Increase Under the Influence of IL-2 and After
Prestimulation With DC/DCleu
It is well known, that DC/DCleu are professional
stimulators of T cells, thereby giving rise to antileukemic
active effector cells after MLC (containing IL-2).
We generated DC/DCleu from healthy or leukemic
MNC or WB (DCleu were only analyzed in cases where the
amount of DC were Z10%) and achieved the following
results.
“MNC-Healthy”
With “Kit-D” we generated Ø 10.79%±2.07%, with
“Pici 1” 15.42%±4.97% and with “Pici 2”
15.33%±6.09% DC in MNC.
“WB-Healthy”
With “Kit-D” we generated Ø 7.44%±1.28%, with
“Kit-I” 11.05%±6.82%, with “Kit-K” 8.62%±2.00%,
with “Kit-M” 8.08%±3.38%, with “Pici 1”
10.50%±2.62% and with “Pici 2” 9.48%±1.85% DC in
WB.
“MNC-AML”
With “Kit-D” we generated Ø 36.51%±7.33% DC
and 6.70%±0.58% DCleu, with “Pici 1” 23.53%±0.00%
DC and 12.63%±0.00% DCleu and with “Pici 2”
19.39%±7.39% DC and 10.20%±0.00% DCleu in
MNC.
“WB-AML”
With “Kit-D” we generated Ø 6.85%±1.10% DC,
with “Kit-I” 13.18%±7.43% DC and 19.95%±0.00%
DCleu, with “Kit-K” 10.48%±3.77% DC and
8.11%±2.38% DCleu, with “Kit-M” 9.92%±3.93% DC
and 13.62%±0.00% DCleu, with “Pici 1”
10.16%±0.00% DC and 8.98%±0.00% DCleu and with
“Pici 2” 12.88%±0.00% DC and 11.39%±0.00% DCleu
in WB.
Pooling all results from the controls without added
response modifiers (“MNC-healthy,” “WB-healthy,” “MNC-
AML,” “WB-AML”) we found Ø 6.28%±2.09% DC.
Here we studied, whether iNKT/NK/CIK cells (in
MNC or WB samples) could contribute to improve the
overall antileukemic activity after stimulation with DC/
DCleu. Therefore, we stimulated in MLC (prepared with
MNC or WB) T-cell–enriched immune reactive cells with
a stimulator cell suspension containing DC/DCleu
(MLC*“MNC-DC” or MLC*“WB-DC”) which were generated
with different “cocktails.” The same setting, but with a
stimulator cell suspension without pretreatment with
“cocktails” (MLC*“MNC” or MLC*“WB”) served as a
control. First, we quantified these cells before and after MLC
with added T cells and IL-2. In a second step, we analyzed
the effect of different “cocktail”-generated DC/DCleu on the
composition of immune reactive cells after stimulation.
Further, we correlated our findings with antileukemic reac-
tivity in a context with iNKT, NK, CIK cells, and T-cell
subsets.
In MLC of Healthy and AML-Patients (MLC*“WB-DC”
or only MLC*“WB”) Proportions of iNKT/NK and
CIK Cells Increase in the Presence of IL-2
At start ofMLCwe found lower total frequencies of iNKT
cells and a shift to higher proportions of T/NK cells coex-
pressing 6B11 in AML patients (n=6) versus healthy WB
samples (n=5; Fig. 6A). In a next step we quantified these
cells after MLC and found that iNKT cells significantly(*)*
increased in both AML and healthy WB-samples after MLC:
at start of MLC versus after MLC*“WB”(AML 6B11+/MLC:
4.18%±1.32% vs. 8.63%±4.40%,P<0.0745*; healthy 6B11+/
MLC: 4.68%±3.92%vs. 12.34%±8.10%,P<0.0305**; healthy
6B11+CD3+/MLC: 4.60%±3.90% vs. 12.11%±8.10%,
P<0.0385**; healthy 6B11+CD3+/CD3+: 5.17%±4.63% vs.
31.77%±22.85%, P<0.0732*; Figs. 6A, B) and start of MLC
versus afterMLC*“WB-DC” (healthy 6B11+/MLC: 4.68%±3.92%
vs. 13.67%±5.01%, P<0.0323**; healthy 6B11+CD3+/MLC:
4.60%±3.90% vs. 13.03%±4.91%, P<0.0393**; 6B11+
CD3+/CD3+: 5.17%±4.63% vs. 21.51%±7.38%,
P<0.0093**, Fig.s 6A, C).
Pooling all results after MLC*“WB-DC” compared with
MLC*“WB”, an astonishing finding was, that cellular com-
positions in healthy samples were comparable in both set-
tings (Figs. 6B, C). This could be due to the general influ-
ence of IL-2 in MLC. However, in AML-cases the
proportions of iNKT cells increased after MLC*“WB-DC”
compared with MLC*“WB” (Figs. 6B, C), although differ-
ences were not significant. Comparable results were found
with MNC as cell sources (dns).
At start of MLC we found lower total frequencies
of CIK and NK cells in AML (n=6) versus healthy
WB-samples (n=5) (Fig. 7A). In a next step we quantified
these cells after MLC and found that CIK and NK
cells (significantly) increased in both AML and healthy
WB-samples after MLC: at start of MLC versus after
MLC*“WB”(AML CD3+CD161+/MLC: 1.41%±0.74% vs.
3.28%±1.59%, P<0.0487**; healthy CD3+CD161+/MLC:
2.35%±2.59% vs. 3.30%±2.04%; AML CD3CD161+/
MLC: 0.15%±0.15% vs. 1.62%±1.81%; healthy CD3
CD161+/MLC: 1.41%±2.48% vs. 0.80%±0.86%; Figs. 7A,
B) and start of MLC versus after MLC*“WB-DC” (AML
CD3+CD161+/MLC: 1.41%±0.74% vs. 3.15%±2.13%;
healthy CD3+CD161+/MLC: 2.35%±2.59% vs.
4.20%±2.02%; AML CD3CD161+/MLC: 0.15%±0.15%
vs. 1.73%±1.98%; healthy CD3CD161+/MLC: AML
1.41%±2.48% vs. 0.57%±0.37%; Figs. 7A, C).
Pooling all results after MLC*“WB-DC” compared with
MLC*“WB”, an astonishing finding was, that cellular com-
positions in healthy samples were comparable in both set-
tings (Figs. 7B, C). This could be due to the general influ-
ence of IL-2 in MLC.
Moreover, we determined values of IL-10, IL-17A,
IFN-g and MCP-1 after MLC*“WB-DC”, MLC*“WB”, WB-
DC culture and WB-DC control in the supernatant of
samples from AML patients (n=4) using ELISA. An
increased cytokine release was shown for IL-17A, MCP-1
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and IL-10 in WB-DC supernatants compared with WB-DC
control—what correlated with higher DC counts compared
with control. An increased release of the chemoattractant
MCP-1 was found after MLC*“WB-DC” with all DC-
generating methods/Kits compared with MLC*“WB”. An
increased antitumor and anti-inflammatory cytokine profile
(IL-17A and IL-10) was found after MLC*“WB-DC” espe-
cially with Kit-M pretreated WB (dns) compared with
MLC*“WB”.
In summary iNKT as well as CIK and NK cells
increased after MLC independent of the stimulator cell
suspension, what might be explained by a general iNKT,
NK, and CIK cells inducing effect by IL-2. AML samples
treated with “cocktails” and used as stimulator cells seemed
to increase iNKT but not CIK and NK cell counts com-
pared with not pretreated controls, pointing to an “iNKT-
inducing influence” of these different “cocktails.”
Highest iNKT Frequencies After MLC Could be
Found in Cases With DC Generation Conducted
With Prostaglandin-containing “Cocktails”
Studying the influence of different DC/DCleu, gen-
erated with “cocktails,” on the frequencies of 6B11 +iNKT
cells after MLC showed, that in MNC/WB samples iNKT
cell proportions increased in general during the MLC.
For each individual patient we defined the best stimulator
cell source resulting in the “highest” (+ + +) 6B11+
iNKT cell frequencies after MLC (Ø6B11+ /WB:
24.91%±19.61%, Ø6B11+/MNC: 10.98%±7.05%);
in “high” (+ +) 6B11+ iNKT cell frequencies (only
defined for WB, Ø6B11+/WB: 13.56%±6.59); with a
“good” (+) frequency of 6B11+ iNKT cells (Ø6B11+/
WB: 8.06%±2.77%; Ø6B11+ /MNC: 5.88%±4.42%)
and with “no increase” () or even in a decrease of iNKT
cells (Ø6B11+/WB: 3.94%±2.45%, Ø6B11+/MNC:
0.93%±0.21%). Frequencies were applied for healthy and
AML samples.
Similar distributions were found for 6B11+CD161+
and 6B11+CD3+ iNKT cells. We could show that espe-
cially in cases in that the DC generation was performed
with prostaglandin-containing (PGE1, PGE2) “cocktails”
the percentages of iNKT cells increased the most (Kit-D,
Kit-K, Kit-M, “Pici1,” “Pici2,” Fig. 8.1) Moreover, we
found that in almost every given patient (except P1433) we
could select at least one of several “cocktails,” that
increased iNKT proportions— pointing to an effect of a
certain pretreatment with “cocktails” on the frequencies of
iNKT cells in healthy as well as of AML samples. Effects
seen in MNC and WB samples from healthy and AML
samples were comparable (Figs. 8.1A, B). Comparable
effects were found for CIK cells (dns).
Moreover, we correlated percentages of 6B11+/
6B11+CD3+/6B11+CD161+ iNKT cells (defined as
“highest,” “high,” “good,” and “no increase”) after MLC
in MNC (Fig. 7.1A, healthy “MNC”) for each individual
sample with the frequencies of DC after culture of healthy
MNC (n=8) with different “cocktails.” We found that
samples with the “highest” (Ø6B11+/MNC:
10.98%±7.05%) frequencies of iNKT cells showed
(although not significant) higher percentages of DC after
the DC-generating process compared with MLC with “no





















































FIGURE 6. Frequencies of iNKT cells before (A) or after (B, C) MLC (WB) are given. T cell-enriched immune reactive cells were
stimulated with a stimulator cell suspension without pretreatment of WB (MLC*“WB”1 (control)) (B) or with a stimulator cell suspension
pretreated with “cocktails” (MLC*“WB-DC”2) (C). 1MLC*“WB” T-cell enriched immune-reactive cells were stimulated with a stimulator cell
suspension without pretreatment of WB with “cocktails”. 2MLC*“WB-DC” T-cell-enriched immune-reactive cells were stimulated with a
stimulator cell suspension pretreated with “cocktails,” “cocktails”= all DC-generating methods/Kits. DC indicates dendritic cells; iNKT,
invariant natural killer T; MLC, mixed lymphocyte cultures; WB, whole blood.
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decrease of iNKT cells (Ø DC-counts: 12.87%±5.44% vs.
9.11%±8.81%; Fig. 8.2). Those correlations were not
found for MNC of the 2 AML-patients we have analyzed
(dns). In a next step, we correlated these values with DC/
DC-subtype values obtained from 5 healthy and 6 AML-
WB samples and did not find correlations between DC/DC
subtype counts and iNKT cells after MLC (dns).
In summary, differences in iNKT cell compositions
after MLC could be found in individual samples (healthy
or AML) after pretreatment with different “cocktails.”
Highest percentages were found with prostaglandin-
containing methods. Together, high frequencies of DC
correlated with “highest” frequencies of iNKT cells after
MLC in MNC of healthy controls, while lower percentages
of DC correlated with “no increase” or even a decrease of
iNKT cells after MLC in MNC of healthy controls—
however, these correlations were not found for the 2 AML
patients analyzed.
Physiological Hypoxia Does Not Influence
Frequencies and Compositions of iNKT, NK, and
CIK Cells Compared With Normoxic Conditions
Under physiological conditions the O2-concentration
in PB is lower than the normoxic 21%. With some
preliminary experiments, we wanted to work out results
under physiologically most adapted conditions in order to
draw first conclusions for the functional relevance on
immune-reactive cells: physiological low O2 concentrations
could possibly influence the conversion of blasts to DCleu
and in consequence the composition and reactivity of
immune-reactive cells. Here we studied whether hypoxic
(compared with normoxic) conditions influence the com-
position of iNKT/NK/CIK cells after MLC (in WB sam-
ples). Results included in this chapter were cultured in 6%
or 10% O2 or with varying O2-concentrations between 0%
and 17%. For our evaluations, all results were pooled. In a
first step, we quantified DC-(subtype) proportions in
healthy WB samples (n=4) with or without stimulation
with 3 “cocktails” (Kit-I, Kit-K or Kit-M). We could show
that DC proportions [overall and mature DC (DCmig)] were
not significantly different in cases cultured under normoxic
versus hypoxic conditions (dns).
In a next step, we quantified iNKT/NK/CIK cell
proportions after MLC*“WB-DC” and MLC*“WB” under
hypoxic versus normoxic conditions. Pooling all results
after MLC*“WB-DC” we found comparable proportions of
iNKT/NK/CIK cells after MLC under normoxic versus
hypoxic conditions (dns).
In summary low O2 culture concentrations do not
seem to have neither a significant effect on the generation of
DC nor on the amount and composition of iNKT, NK, and




































FIGURE 7. Frequencies of CIK/NK cells before (A) or after (B, C) MLC (WB) are given. T cell-enriched immune reactive cells were
stimulated with a stimulator cell suspension without pretreatment of WB (MLC*“WB”1 (control)) (B) or with a stimulator cell suspension
pretreated with “cocktails” (MLC*“WB-DC”2) (C). 1MLC*“WB” T-cell enriched immune reactive cells were stimulated with a stimulator cell
suspension without pretreatment of WB with “cocktails.” 2MLC* “WB-DC” T-cell enriched immune reactive cells were stimulated with a
stimulator cell suspension pretreated with “cocktails.” “Cocktails”= all DC-generating methods/Kits. CIK indicates cytokine-induced
killer; DC, dendritic cells; MLC, mixed lymphocyte cultures; WB, whole blood.
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iNKT, NK, CIK Cells Contribute to Antileukemic
Activity
As shown above iNKT cell proportions increase after
MLC*“WB-DC” or MLC*“MNC-DC”. Here we studied, whether
iNKT/NK/CIK cells could contribute to improve the overall-
antileukemic activity after MLC. In a first step, we quantified
these cells and their subtypes in individual AML-WB samples
(precultured with various “cocktails”) after MLC (with added
T cells and IL-2). In the next step, we correlated frequencies of
iNKT, NK, CIK cells with the antileukemic activity [blast-lysis
evaluated with a cytotoxicity (fluorolysis) assay] of the indi-
vidual WB samples from AML patients.
We found that cases with versus without an antileukemic
activity (“lysis” vs. “nonlysis”) were characterized by sig-
nificantly*** increased frequencies of 6B11+ iNKT cells in the
totalMLC (7.25%±4.21% vs. 2.60%±0.96%,P<0.0022) and
significantly** higher frequencies of 6B11+CD161+/6B11+
CD3+ iNKT cells inMLC (3.67%±3.55% vs. 1.06%±0.29%,
P<0.0083; 5.10%±2.57% vs. 2.12%±1.04%, P<0.0232,
Fig. 9A). However, the subtype-compositions of iNKT and CIK
cell subsets were comparable in the 2 groups compared (6B11+
CD161+/CD161+: 52.63%±24.14% vs. 51.34%±9.10%;
6B11+CD3+/CD3+: 18.45%±15.34% vs. 17.25%±9.79%;
CD3+CD161+/CD3+: 15.08%±14.03% vs. 14.88%±5.34%,
8.1. Frequencies of iNKT-cells (subsets) after MLC
Healthy ‘MNC’ Kit-D ‘Pici1’ ‘Pici2’ control
P1418 + +++ - +
P1421 + + +++ +
P1422 + +++ + +
P1425 +++ +
P1428 + +++ +
P1429 +++ - -
P1436 +++ + +++
P1438 +++ + + +
AML ‘MNC’ Kit-D ‘Pici1’ ‘Pici2’ control
P1424 - - +++
P1426 +++ + - +
6B11+/6B11+CD3+/6B11+CD161+-iNKT-cells after MLC*‘WB-DC’ and MLC*‘WB’
6B11+/6B11+CD3+/6B11+CD161+-iNKT-cells after MLC*‘MNC-DC’ and MLC*‘MNC’
Healthy ‘WB’ Kit-D Kit-I Kit-K Kit-M ‘Pici1’ ‘Pici2’ control
Kit-D Kit-I Kit-K Kit-M ‘Pici1’ ‘Pici2’ control
P1420 +++ + + ++ + + ++
P1428 + + +++ ++ + ++ ++
P1429 ++ + + + ++ + +++
P1436 + +++ + +
P1438 - - - +++ ++ - +
AML ‘WB’
P1424 +++ - - - - - -
P1426 ++ + + + + +++
P1430 + + +++ ++
P1433 - -
P1434 +++ +++ ++ +
P1439 +++ ++










FIGURE 8. Frequencies of iNKT cells (6B11+ or 6B11+CD3+ or 6B11+CD161+ iNKT cells) after MLC (MNC and WB) are given. T cell-
enriched immune reactive cells were stimulated with a stimulator cell suspension without pretreatment of MNC/WB [MLC*“MNC/WB”1
(control)] (B) or with a stimulator cell suspension pretreated with “cocktails” (MLC*“MNC/WB-DC”2) (C). AML indicates acute myeloid
leukemia; DC, dendritic cells; iNKT, invariant natural killer T; MLC, mixed lymphocyte cultures; MNC, mononuclear cells; WB, whole
blood. MNC/WB: “+ + + ” “highest” counts of iNKT cells; “+ + ” “high” counts of iNKT cells, “+ ” “good” counts of iNKT cells, “-” “no”
increase or decrease of iNKT cells.
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Fig. 9B). Moreover, significantly* higher proportions of CD3+
CD161+ CIK cells in MLC (3.26%±2.35% vs. 1.85%±0.48%,
P<0.0509) and significantly*** increased frequencies of
CD3CD161+ NK cells in MLC were found in cases with
versus without an antileukemic activity (2.07%±2.13% vs.
0.21%±0.13%, P<0.0023, Fig. 9C). However, significantly*
higher proportions of proliferating T cells (Tprol: CD3
+
CD69+/MLC) and significantly** higher frequencies of central
memory T cells (Tcm: CD3
+CD45RO+CCR7+/MLC) were
found in cases with versus without an antileukemic activity
(Tprol: 17.56%±7.86 vs. 15.29%±2.61%, P<0.0825, Tcm:
9.35%±10.47% vs. 2.32%±1.5%, P<0.01451, Fig. 9D).
No significant differences were found in the composition of
naive/non-naive T cells in the groups compared (dns).
Moreover, we assorted our samples according to their
antileukemic activity (“lysis” vs. “nonlysis”) and evaluated
predictive cutoff values for NK/CIK/iNKT cells after
MLC*“WB-DC” and MLC*“WB”. A total of 100% of samples
with >4% 6B11+ iNKT cells, with > 4% 6B11+CD3+
iNKT cells and with >1.5% 6B11+CD161+ iNKT cells
after MLC*“WB-DC” and MLC*“WB” showed antileukemic
activity (lysis). Furthermore, 100% of samples with >2.3%
CD3+CD161+CIK cells and with >1.9% CD3+CD56+
CIK cells after MLC*“WB-DC” and MLC*“WB” showed
antileukemic activity. Moreover, 89%–100% of samples
with >0.4% CD3CD161+ NK cells and with >1.3%
CD3CD56+ NK cells after MLC*“WB-DC” and
MLC*“WB” showed antileukemic activity.
Further, we analyzed whether the addition of
“cocktails” to cultures improves the antileukemic activity
after MLC compared with controls. Samples with more
lysis compared with controls, were defined as improved
blast-lysis, samples with less lysis compared with controls
as “not improved” blast-lysis. Samples with improved
blast-lysis showed significantly* higher 6B11+ iNKT cell













































































FIGURE 9. Frequencies of iNKT cells (A), CIK cells (B), NK cells (C), and T cell subsets (D) after MLC (MNC/WB) are given. T cell-
enriched immune reactive cells were stimulated with a stimulator cell suspension without pretreatment of MNC/WB [MLC*“MNC/WB”1
(control)] or with a stimulator cell suspension pretreated with “cocktails” (MLC*“MNC/WB-DC”2) were compared in cases with/without
blast lysis. Results were obtained with a cytotoxicity (fluorolysis) assay. CIK indicates cytokine-induced killer; iNKT, invariant natural killer
T; MLC, mixed lymphocyte cultures; NK, natural killer; Tprol, proliferating T cells (CD69+CD3+), Tcm, central-memory T cells
(CD45RO+CCR7+).
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blast-lysis (7.94%±4.12% vs. 4.39%±3.12%, P<0.0921).
Moreover, samples with improved blast-lysis showed (ns)
higher frequencies of 6B11+CD161+ and 6B11+CD3+
iNKT cells compared with samples with not improved blast-
lysis (4.82%±3.49% vs. 1.80%±2.90%; 5.25%±2.13% vs.
3.50%±1.84%). Furthermore, samples with “improved”
blast-lysis showed (ns) higher frequencies of CD3+CD161+
CIK cells and CD3CD161+ NK cells compared with sam-
ples with not improved blast-lysis (3.99%±2.51% vs.
2.10%±1.83%; 2.73%±1.95% vs. 0.95%±1.87%).
Furthermore, we correlated findings of ELISA of
supernatants of MLC*“WB-DC” and MLC*“WB” of samples
from AML patients (n=4) with antileukemic activity
(“lysis” vs. “no lysis”). We could show that cases with
achieved “lysis” compared with “no lysis” after MLC*“WB-
DC”/MLC*“WB” were characterized by higher release of
antitumor and anti-inflammatory cytokines (IL-17A and
IL-10), what correlated with higher iNKT, NK, and CIK
cell frequencies.
With one exemplary experiment, we could show that a
radiation of stimulator-cells did not reduce proportions of
T/iNKT/NK and CIK cells; however, reduced the overall
blast-lysis compared with unirradiated settings. This could
point to a role of iNKT/NK and CIK cells beside T cells in
antileukemic reactions (dns).
In summary in cases with antileukemic blast-lytic
activity after MLC not only a T cell stimulation was
induced, followed by a creation of memory T cells, but also
that iNKT, NK, CIK cell proportions are significantly
increased—pointing to an involvement of these cells in
antileukemic reactions. Moreover, the presence of increased
proportions (above cutoff values) of iNKT as well as of
CIK and NK cells after MLC might correlate with suc-
cessful blast-lysis.
DISCUSSION
Role of T, iNKT, NK, and CIK Cells in Tumor-
immune Surveillance
T, iNKT, NK, and CIK cells and their subsets are
important mediators of immune responses: T cells are known
to be activated by tumor or leukemia antigen-presenting DC
and—as shown exemplarily by our DC/DCleu ex vivo
strategies—their antitumor functionality can be improved by
DCleu.
9 Teff-em enable—in case of a secondary challenge—a
very quick and immediate secondary immune response,
while Treg are able to downregulate immune responses—
important to inhibit autoaggressive immune reactions—but
also in a context to downregulate antitumor responses.9,10 In
contrast to T cells, iNKT, NK, and CIK cells react quickly
to an immunologic threat by secreting cytokines and che-
mokines4,30 and kill tumor cells without prior activation and,
unlike T and iNKT cells, NK and CIK cells do not recognize
target cells by a TCR.5 iNKT cells can produce a variety of
chemokines and cytokines like IFN-g, IL-4/IL-2/IL-12,
tumor necrosis factor (TNF)-a, transforming growth factor-
b, and GM-CSF that in consequence activate different cells
like DC, NK cells, CD4+/CD8+ T cells, but also Treg.
31,32
A previous study could show that all subsets of iNKT cells
produce almost the same amounts of IFN-g and TNF-a,
while IL-4 is mainly produced by PB-CD4+ iNKT cells.13
Moreover, iNKT cells show a strong cytolytic potential and
can directly kill tumor cells as they express granzyme-B,
Perforin, and FasL.4,31 Therefore, it might be promising to
use or even to increase the antileukemic potential of NK,
CIK cells and especially iNKT cells to enhance the patients’
anti-tumor immune response.
Methods to Detect iNKT, NK, and CIK Cells
The identification and quantification of iNKT cells
(in healthy blood samples) is known to be difficult due to
their low frequency as well as missing marker (combina-
tions). Previous methods using CD1d tetramers or the
combination of Va24-/Vb11-antibodies did not yield the
necessary specific results.13 Therefore, the first aim of our
study was to develop a highly specific iNKT cell detection
panel for the quantification of iNKT cells/subsets in
healthy, but also to be used for leukemia patients. Fur-
thermore, we compared strategies and markers to detect
and quantify NK and CIK cells and their subsets in
healthy, but especially in leukemic patients. A previous
study performed with healthy samples could show that a
new moAb (clone 6B11-PE) can recognize the invariant
CDR3 loop of the Va24Ja18-TCR rearrangement on the
cell surface and can be used to specifically characterize
iNKT cells in combination with anti-CD3.13 In our current
study, we also used 6B11-PE, but also 6B11-FITC (pur-
chased from different companies) to characterize and define
iNKT cells. In previous studies,11,13 only 6B11-PE was used
for analysis, but not 6B11-FITC. We found (significantly)
higher proportions of iNKT cells detected with 6B11-FITC
compared with 6B11-PE in AML, ALL, CLL patients. The
proportions of iNKT cells detected with 6B11-FITC com-
pared with 6B11-PE were (significantly) lower in healthy
samples. Moreover, 6B11-FITC-stainings seemed to yield
varying results in several stainings, whereas 6B11-PE-
stainings showed stable and precise results for iNKT
detection. It is well known, that moAbs can react and bind
differently to their targets—depending not only on the
selected clones, but also on the purchasing companies, the
fluorochromes used or the combination with partner
moAbs in a panel.33 In order to exclude these variations, we
focused mainly on 6B11-PE results in our setting.
Coexpression analyses of 6B11 with myeloid (eg, CD33,
CD34, CD117) or lymphoid (eg, CD1a, CD5, CD7, CD10,
CD19, CD20) markers on blasts from malignant myeloid and
lymphoid cell lines showed, that 6B11 was not expressed on
myeloid or B-lymphoid blasts. However, we found a low
expression of 6B11 on T-linear cells of the Jurkat cell line. As
we do not know, whether this cell line has a Va24-/Vb11-
rearrangement, typical for iNKT cells we cannot decide
whether this expression is “aberrant” on this cell line or spe-
cific. In general, our results show, that the 6B11-PE-marker,
but not 6B11-FITC, can be regarded as a very specific marker
to detect iNKT cells without cross-reactivity or aberrant
expression on leukemic cells. Previous studies did not analyze
whether 6B11 is aberrantly expressed on leukemic blasts and if
6B11-FITC is specific for iNKT cells analyses. Thereby, we
can confirm preliminary findings of other groups, that the
detection of iNKT cells with 6B11 alone or in combination
with subtype markers is very precise, as 6B11 specifically
recognizes the CDR3 loop of the invariant TCR of CD1d-
restricted iNKT cells.13
It is known, that the iNKT cell population consists of
different subsets with diverse phenotypic and functional
characteristics that can be subdivided according to their
expression of surface molecules, receptors, effector func-
tionality or tissue localization.4 In a former study it was
shown that 6B11 could be used in combination with further
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T (CD27, CD28, CD45RA, CD45RO) and NK cell mark-
ers (CD16, CD56, CD161) to analyze iNKT subsets.13
Moreover, iNKT cells were characterized by the combina-
tion of CD1d and CD3 or the combination of Va24 and
Vb11. The percentage of iNKT cells expressing CD4 or
CD8 was evaluated in a region comprising 6B11+CD3+
iNKT cells. Like the previous study, we used 6B11 in
combination with CD3, CD45R0, and CD161. Moreover
we included the combinations of 6B11 with CD1d, Va24,
CD4 or with CD8. This means that we evaluated the
expression of T cell (CD1d, CD3, CD45RO, Va24) and NK
cell markers (CD161) on 6B11+ iNKT cells and divided
them into “T cell-like” and “NK cell-like” iNKT subsets.
We are the first group, that defined “T cell-like” iNKT
subsets as CD3+6B11+, CD4+6B11+, CD8+6B11+,
Va24+6B11+, CD1d+6B11+, CD45RO+6B11+, and
CD45RO6B11+ iNKT cells.
Classically, iNKT cells have been identified with
CD1d-tetramers loaded with a-galactosylceramide, but this
method could lead to an overestimation of iNKT cells as
some T cell subsets also express CD1d.13 This study did not
find significant differences in 6B11+ iNKT cells compared
with CD3+6B11+ iNKT cells or CD3+CD1d+ iNKT
cells in healthy samples. Although we did not combine
CD1d with CD3, but with 6B11, we could also show that
frequencies of 6B11+CD3+ and 6B11+CD1d+ iNKT
cells were comparable in healthy samples. We could show in
addition that frequencies of 6B11+CD3+ and 6B11+
CD1d+ iNKT cells were similar in AML, ALL, and CLL
samples. Unlike the previous study,13 we detected higher
numbers of 6B11+ iNKT cells compared with 6B11+
CD3+ and 6B11+CD1d+ iNKT cells in healthy samples
as well as in AML, ALL, and CLL samples.
Using CD3-/Va24-antibodies, we could demonstrate
specific results and detected lower frequencies of Va24+6
B11+ iNKT cells compared with CD3+6B11+ iNKT
subsets in healthy as well as in AML, ALL, and CLL
patients. These findings are consistent with a previous
study, which found 3 times more CD3+6B11+ iNKT cells
compared with CD3+Va24+Vb11+ iNKT cells in
healthy adult and children’s samples.11 However, this group
combined Va24 with CD3 and Vb11, while we combined
Va24 with 6B11. Unlike these results, another group found
similar proportions of CD3+6B11+ iNKT cells and
Va24+Vb11+ iNKT cells in healthy controls.13 However,
this group used the combination of Va24 and Vb11 without
combining it with CD3. These differences may be explained
by the fact, that different combinations of Va24 with CD3,
Vb11 or 6B11 were used for iNKT cell detection. Fur-
thermore, the results or our group and Bienemann may be
explained by the fact that the invariant a-chain of the TCR
sometimes binds with other b-chains than Vb11, which
could lead to an underestimation of iNKT cells.11
Both type I iNKT cells and type II iNKT cells, are
divided into CD4+, CD4CD8, CD8aa+, and
CD8ab+ iNKT cells, with higher proportions being
CD4+, lower proportions being CD4CD8 and only a
few cells CD8aa+ or CD8ab+, which could only be found
in humans but not in mice.4 Unlike previous studies, we
combined 6B11 with CD4 and CD8 for subtype analyses.
We can confirm that the majority of 6B11+ iNKT
cells coexpresses CD4+ and the minority CD8+ in healthy
samples. We can add as a new finding in addition, that
higher proportions of 6B11+CD4+ iNKT cells and lower
proportions of 6B11+CD8+ iNKT cells were also found
in AML, ALL and CLL patients. A previous study sug-
gested that CD4+ iNKT cells produce both Th1 and Th2
cytokines, whereas CD4 iNKT cells tend to produce
mainly Th1 cytokines.31 However, another study found that
CD4+, CD4, and CD8+ iNKT cells produced similar
amounts of IFN-g and TNF-a, but CD4+iNKT cells
produced significantly more IL-4.13 In our patients’ cohort,
we had not further analyzed the functional role of CD4 and
CD8 expressions on iNKT cells. However, we suggest to
combine 6B11 with CD4 and CD8 to analyze the diffences
between 6B11+CD4+, 6B11+CD4, 6B11+CD8+, and
6B11+CD8 iNKT cells.
Consistent to a previous study we found that the
majority of iNKT cells is CD45RO+6B11+, while the
minority is CD45RO6B11+, what could be interpreted as
iNKT cells with a memory-effector phenotype.13
We defined “NK-like” iNKT cells as CD161+6B11+
iNKT cells and found lower proportions of CD161+6
B11+ iNKT cells compared with 6B11+ iNKT cells and
6B11+CD3+ iNKT cells (“T-like” iNKT cells). A pre-
vious study showed different NK cell markers expressed by
iNKT cells and demonstrated that the majority of iNKT
cells expressed CD161, while only a minority expressed
CD56 and CD16. Furthermore, this study showed that
CD161 was expressed on significantly higher frequencies of
CD8+ or double negative iNKT cells compared with
CD4+ iNKT cells. CD161 (KLRB1) is a C-type lectin
receptor expressed on human NK cells, but also on iNKT
and T cell subsets—especially on subgroups found in liver
and gut.13–15,18 In humans, the CD161 receptor interacts
with its ligand LLT1 and suppresses the cytotoxic potential
of NK cells. Moreover, it was shown that an infection with
cytomegalovirus leads to decreased expression of CD161 on
NK cells.34
In conclusion, we suggest that the most precise
detection of iNKT cells should be based on 6B11-PE alone
or in combination with CD3 and CD161-moAbs. More-
over, we found new detection methods for iNKT cells/
subsets using 6B11 in combination with CD1d, Va24, CD4
or CD8. Furthermore, we could demonstrate that 6B11 can
be used to analyze iNKT cells of leukemia patients,
knowing that there is no aberrant expression of 6B11 on
blasts. Our results confirm the heterogeneity of iNKT cells,
as we could show that there are various “T cell-like” and
“NK cell-like” iNKT subsets. This highlights that the
iNKT cell population consists of several phenotypically and
potentially functionally different subsets with diverse sur-
face markers. A previous study could demonstrate that
neonatal CD4+, adult CD4+, and adult CD4 iNKT
cells are phenotypically diverse and show different effector/
memory T-cell markers and NK cell markers. Neonatal
CD4+ iNKT cells show a more naive phenotype and can
be modified more easily in their capacity to acquire Th1-like
or Th2-like functions compared with adult iNKT cells,
which are mainly resistant to functional reprogramming,
but show higher cytotoxic functions.35
To detect NK and CIK cells, we used recommended
combinations of CD3 with CD161 or CD56 moAbs. NK
cells were defined as CD3CD56+ or CD3CD161+cells
and CIK cells were defined as CD3+CD56+ or CD3+
CD161+cells. Both combinations detect similar amounts
of NK and CIK cells in healthy controls. However, CD56 is
known to be aberrantly expressed on blasts of certain
AML-subtypes and correlates with a worse prognosis.36 In
these cases, NK cells cannot be evaluated with a CD56-
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marker. We recommend using the CD161-moAb to quan-
tify NK cells in cases with aberrant expression of CD56.
Therefore, CD161 can be regarded as a better NK and CIK
cell marker for leukemic patients with aberrant CD56
expression.
In conclusion, we suggest that NK and CIK cells can
always be detected with the combination of CD3 with
CD161-moAbs and with CD3 and CD56-moAbs in cases
without aberrant expression of CD56. The potential func-
tional differences in these subsets, however, should be
evaluated.
iNKT, NK, and CIK Cells in AML, ALL, and CLL
Patients Compared With Healthy Samples
The present study shows that AML, ALL as well as
CLL patients’ MNC are characterized by (significantly)
lower frequencies of CIK cells (CD3+CD56+ or
CD161+), NK cells (CD3CD56+ or CD161+) and
iNKT cells (6B11+, 6B11+CD3+ or CD8+ or CD161+
or Va24+) compared with healthy donors. This could be
confirmed by another group that demonstrated significantly
lower median values of NK cells, NKT, and iNKT cells in
AML patients compared with healthy donors’ PB (cells/mL:
303.47 vs. 101.54; 55.86 vs. 21.85; 0.515 vs. 0.0814).7
However, this group did not compare values of CIK cells in
AML patients versus healthy and did not consider different
NK and iNKT subsets: NK and NKT cells were detected
with CD3 and CD16/56 and iNKT cells with CD3 in
combination with Va24 and Vb11.7 In general, these find-
ings can be expected due to the displacement of immune-
reactive cells by uncontrolled proliferating and expanding
blasts.
In summary, we could show that a high blast-load in
AML, ALL or CLL patients directly correlated with low
frequencies of iNKT, NK, and CIK cells. Therefore, the
majority of iNKT, NK, and CIK cells is displaced by blasts
in AML, ALL, and CLL patients.
An interesting finding was, that—although pro-
portions of iNKT, NK, and CIK cells were comparable in
leukemic patients, their subtype composition was different
in leukemic patients compared with healthy donors show-
ing a shift to (significantly) higher frequencies of T and NK
cells coexpressing 6B11 in AML, ALL, and CLL patients
compared with healthy donors. This might suggest that
certain T/NK-derived iNKT cells in leukemic patients
might either be subtypes with downregulated antileukemic
functionality or could be special subsets that could be
triggered in antileukemic reactivity.
In summary, we present the new finding that pro-
portions of iNKT, NK, and CIK cells were significantly
lower in AML, ALL, and CLL patients and compared
with healthy donors. Their subset compositions as well
as iNKT subsets were comparable in AML, ALL, and
CLL patients. We can demonstrate in addition to find-
ings in the literature a shift to higher proportions of
T and NK cells expressing 6B11 in AML, ALL, and CLL
patients compared with healthy donors, what might
point to comparable mechanisms in leukemic diseases,
that favor the extension of subsets in these diseases and
what might help to develop new iNKT, NK, and CIK
cell–based immune therapeutic strategies for leukemia
patients.
Prognostic Relevance of iNKT, NK, and CIK Cells
in AML, ALL, and CLL Patients
A previous study could show, that the overall number
of iNKT cells in AML patients is an important prognostic
factor as iNKT cell proportions >0.2 cells/mL are asso-
ciated with favorable survival.7 Furthermore, this study
could demonstrate, that a lower number of iNKT cells in
PB in combination with higher proportions of CD4+ and
CD8+ T cells in BM at diagnosis is characterized by a
lower overall survival (OS) in AML patients. Another study
could demonstrate that a high expression of NKp30/
NKp46 on CD16+ NK cells in elderly AML patients
correlated with leukemia-free and better OS.37 Moreover,
previous studies pointed out that CIK cells (especially
CD3+CD56+) show strong cytotoxic potential, for
example against leukemia,4,30 but did not correlate the
frequencies of CIK cells with survival or favorable prog-
nosis for leukemia patients. With our results we confirm
these findings and can add in addition, that higher per-
centages of iNKT, NK, and CIK cells correlate with the
allocation of patients to diverse prognostically more
favorable subgroups not only in AML, but also in ALL and
CLL.
We could show, that higher frequencies of iNKT cells
in leukemic patients correlate with prognostically better
subsets in AML, adult ALL, and CLL patients. AML
patients with favorable (vs. adverse) NCCN risk score
showed higher percentages of 6B11+, 6B11+CD161+,
and 6B11+Va24+ iNKT cells. Moreover, AML and CLL
patients younger (vs. older) than 60 years showed higher
numbers of 6B11+, 6B11+CD161+, 6B11+CD3+, and
6B11+Va24+ iNKT cells. AML patients with primary
(vs. secondary) AML showed higher frequencies of 6B11+
and 6B11+CD3+ iNKT cells. Furthermore, AML and
adult ALL patients without (vs. with) extramedullary foci
showed higher frequencies of 6B11+, 6B11+CD3+,
6B11+CD161+, and 6B11+Va24+ iNKT cells. More-
over, adult ALL patients achieving CR after GMALL
induction chemotherapy (vs. NCR) and CLL patients with
no need (vs. need) for therapy showed higher frequencies of
6B11+, 6B11+CD3+, and 6B11+Va24+ iNKT cells.
AML and CLL patients with stable CR (vs. no stable CR:
relapse or death by disease) showed (significantly) higher
percentages of 6B11+, 6B11+CD3+, and 6B11+
CD161+ iNKT cells, however, 1 patient had died from
pneumonia. This data can confirm previous findings7,37,38
that low frequencies of iNKT cells can be correlated with
worse prognosis and worse OS. In contrast to previous
studies and our results, another study found that lower
frequencies of NK and NK like T cells correlated with
higher survival in AML patients, while higher frequencies
were correlated with poor survival.7,37,38
Moreover, we could show, that higher frequencies of
NK cells in leukemia patients correlate with prognostically
better subsets in AML, adult ALL, and CLL patients.
AML patients without (vs. with) extramedullary foci
showed (significantly) higher frequencies of CD3CD56+
NK cells. Moreover, adult ALL patients, who had achieved
CR after GMALL induction chemotherapy, showed higher
numbers of CD3+CD161+ NK cells. Furthermore, AML
and CLL patients, who stayed in stable CR (vs. no stable
CR) showed higher amounts of CD3CD161+ and
CD3+CD56+ NK cells. Consistent to previous stud-
ies,7,37,38 our data show that higher percentages of NK cells
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can be correlated with better prognosis and stabilization of
disease. In contrast to a previous study, we could not cor-
relate low frequencies of NK cells with better survival.7,37,38
We can add in addition, that higher frequencies of
CIK cells in leukemia patients correlate with prognostically
better subgroups in AML and CLL patients. AML patients
who achieved CR (vs. NCR) and CLL patients with no
need for initial therapy (vs. need for initial therapy) showed
(significantly) more CIK cells. Moreover, AML as well as
ALL patients without extramedullary foci presented with
significantly more CIK cells. Furthermore, AML and CLL
patients, who stayed in stable CR (vs. no stable CR),
showed higher numbers of CD3+CD161+ and CD3+
CD56+ CIK cells. Consistent to previous studies,4,30 these
data might point to an antileukemic reactivity of CIK
cells—leading to stabilized disease.
We conclude that higher frequencies of iNKT, NK as
well as CIK cells can be regarded as a favorable prognostic
factor for AML, adult ALL, and CLL patients. For the
future, we recommend to perform subtype-analyses of
iNKT, NK as well as CIK cells in more detail to be able to
allocate defined subtypes to prognostic groups. Moreover,
we recommend multifactorial statistical analyses to work
out the role of cellular partners involved in the mediation of
anti-leukemic reactions and better prognosis for individual
pts in more detail.
iNKT, NK, CIK Cells Contribute to Antitumor and
Antileukemic Activity
A previous study has shown, that iNKT cells are
important mediators in tumor-protection, as reduced fre-
quencies of iNKT cells were correlated with a variety of
cancers and increased frequencies of iNKT cells were
related with favorable response to therapy.39 Another study
showed, that NK and CIK cells have cytotoxic potential
against leukemia and other cancers.30,40–42
In the current study, we could show in general, that
higher proportions of iNKT, NK, and CIK cells and higher
frequencies of proliferating T cells and Tcm correlated with
antileukemic activity (blast-lysis). Moreover, we could
show (although only with one exemplary experiment up to
now), that radiation of stimulator-cells did not reduce
proportions of T/iNKT/CIK and NK cells, but reduce the
overall blast lysis of (stimulator cell activated) effector cell-
mediated antileukemic activity compared with unradiated
settings—what could be explained by a functional knock-
out of these T/iNKT/CIK and NK cells and therefore point
to their antileukemic contribution. Consistent, a previous
study has shown that in knockout experiments in mice
absence of iNKT cells was correlated with tumor-growth
and poor survival, while a transfer of iNKT cells into mice
could reduce tumor growth.39 All of these results emphasize
the relevance of iNKT/CIK and NK cells in antileukemic
reactions. More studies have to be performed to work out
the specific role of these cell fractions in the mediation of
antileukemic reactions. To further analyze the function of
different iNKT/CIK or NK cells and their subtypes we
recommend performing, for example blocking experiments
knocking out certain cellular subtypes and correlating
results with antileukemic function.
With an attempt to evaluate the predictivity of iNKT/
CIK and NK cell frequencies we defined cutoff values: we
could show that cases presenting with higher values of
iNKT (subtypes) or CIK or NK cells were characterized by
a higher chance to belong to the group with “antileukemic
activity.”
In summary, we suggest to define and applicate cut-off
values for iNKT/CIK and NK cells and their subtypes for
leukemia-pts in the future to enable a refined estimation of
prognosis.
Induction of iNKT, NK, and CIK Cells After
Stimulation With DC/DCleu
It was already shown, that a crosstalk between NK
cells and DC improves antitumor reactions. Recently,
details about the mechanisms behind the increase of
antitumor-reactivity (eg, pathogen-associated molecular
patterns or cytokines) have been detected.39,43 Moreover
cytokines, cellular factors, antibodies promote NK cell
activations, and DC-NK crosstalk establishing a micro-
environment which enables antitumor reactions.44,45
Moreover, a crosstalk between CIK cells and DC has been
reported recently, demonstrating an influence of a DC
stimulation on the phenotype as well as antileukemic
cytotoxicity of CIK cells.46 Recently a crosstalk between
DC and iNKT cells has been shown (mediated, eg, by
chemokine receptor-expression), leading to an amplification
of antitumor-immune reactions.4,47
With our data, we contribute that iNKT cells not only
respond to a stimulus with IL-2, but in addition are sig-
nificantly expanded in cases with previous treatment of
AML-or healthy MNC/WB with “cocktails.” Comparable
phenomena were found for CIK cells. These finding might
point to an induction of these cell-populations by DC/
DCleu stimulation.
Moreover, we can add important new data to a pre-
vious study that highlighted 3 possible mechanisms of
antitumor-reactivity mediated by iNKT cells: indirect
cytotoxicity, direct cytotoxicity and modulation of the
tumor microenvironment. “Indirect cytotoxicity” means
that iNKT cells and DC stimulate each other by TCR/
CD1d and CD40/CD154 interactions leading to a release of
cytokines (e.g. IL-10, IL-17A, IFN-g, and IL-12) and
increased antitumor activity of other effector cells.39,43
Mature DCs are known to produce IL-12 stimulating
iNKT cells to increase IFN-g release coactivating NK cells
and their production of IFN-g,39 what could in return lead
to a release of pro-inflammatory cytokines by DC.43 Our
preliminary data obtained with some cases in part confirm
these findings: increased release of cytokines (IL-17A, IL-
10) correlated with achieved “lysis”/antitumor activity and
with higher iNKT, NK and CIK cell frequencies—pointing
to a cytokine-mediated antitumor activity.39 Moreover, we
could show that “highest” iNKT cell frequencies were
correlated with higher DC—pointing to a coactivation
between iNKT cells and DC.
Recently it was shown, that soluble as well as cellular
components of the immune-system are involved in a
“crosstalk” with NK/iNKT cells leading to a “cross-pri-
ming” in infectious diseases or cancer: for example, IL-21
improved cytotoxicity and increased IFN-g production of
NK cells against breast cancer cells,48 TH17 frequencies
directly correlated with iNKT frequencies and good prog-
nosis in CLL49 and iNKT cells were shown to be involved
in cross-talk between DC and CD8+cells—at least in
infectious diseases.50 These findings emphasize the impor-
tance to study these kinds of cross-talks in detail in future
studies.
Boeck et al J Immunother  Volume 40, Number 6, July/August 2017
246 | www.immunotherapy-journal.com Copyright r 2017 Wolters Kluwer Health, Inc. All rights reserved.
Copyright r 2017 Wolters Kluwer Health, Inc. All rights reserved.
We can add in addition that the highest 6B11+ iNKT
and CIK values were found after culture in prostaglandin-
containing “cocktails.” This could point to a special effect of
these “cocktails” on the allocation and recruitment of iNKT
and CIK cells—resulting in an improved antileukemic
activity—up to now an effect of Prostaglandin E2 on the
maturation of DC has been shown.19,28 Alternatively, it might
be discussed, that “only” the 6B11 or CD56-antigens are
upregulated on T/NK cells, however without expansion of
functionally reactive iNKT/CIK cell populations.
Physiologic Culture-conditions (Hypoxia, WB)
Do Not Have an Effect on the Generation of
DC Nor on the Frequencies and Composition
of iNKT, NK or CIK Cells
Preliminary experiments with MNC/WB cultured under
hypoxic versus normoxic conditions did not yield an effect on
the generation of DC nor on the frequencies and composition
of iNKT, NK, and CIK cells after MLC. Although more
experiments have to be performed we can assume, that working
under normoxic conditions yields “physiological” data.
CONCLUSIONS
In conclusion, we recommend to regularly evaluate
proportions of iNKT/NK/CIK cells and include specific
markers in diagnosis panels (based on 6B11/CD161/CD56/
CD3 antibodies) in AML/ALL/CLL for quantitative,
qualitative, and prognostically relevant estimation of indi-
vidual patients antileukemic potential. Detection of iNKT
cells should be based on 6B11-(PE)-staining alone or in
combination with (especially) CD3 and CD161; NK and
CIK cell detection should be based on the combination of
CD3 with CD161 or with CD56 (in cases without aberrant
expression of CD56). As we could demonstrate a shift to
higher proportions of T and NK cells expressing 6B11 in
AML, ALL, and CLL patients compared with healthy
donors, we suggest that mechanisms behind these subtype
extensions have to be studied in detail. These findings
might be considered in the development of iNKT-based
immunotherapies.
Considering that higher frequencies of iNKT, NK,
and CIK cells correlate with prognostically better sub-
groups and with antileukemic activity (blast lysis) in AML,
adult ALL, and CLL patients, high amounts of iNKT, NK,
and CIK cells can be regarded as a favorable prognostic
factor in leukemic patients.
Moreover, proportions of iNKT and CIK cells
increase under stimulation of MLC with IL-2 and partic-
ularly after culture with (prostaglandin-containing) DC/
DCleu-inducing “cocktails”. Cytokine profiling revealed a
correlation of release of antitumor and anti-inflammatory
cytokines with higher frequencies of iNKT, NK, and CIK
cells after MLC, what correlated with improved anti-
leukemic cytotoxicity. These findings not only point to a
cross-talk between soluble factors and these immune reac-
tive cells and DC, but in addition a correlation with an
improved antileukemic reactivity. In conclusion,
“cocktails” not only activate antileukemic T cells, but also
iNKT and CIK cells and improve the antileukemic activity.
Inclusion of prostaglandin-containing DC/DCleu-generat-
ing methods might be especially promising in the recruit-
ment of antileukemic active immune reactive cells.
Although the quantification of these small cell pop-
ulations (using selected markers and special gating-
strategies in flow cytometric settings) has to be performed
from experienced groups and the contribution of these cell
populations to antileukemic reactions should not be
underestimated.
Novel immunotherapeutic protocols in the treatment
of pts with leukemia should be designed, that include the
quantification of iNKT, NK, and CIK cells and their
subtypes in diagnostic panels. Moreover, the role of iNKT,
NK, and CIK cells as well as soluble factors in a cross-talk
in DC/DCleu-triggered antileukemic reactions in AML
patients should be studied in detail and probably be
included in immunotherapeutic protocols against AML.
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